ATE337019T1 - Geladene lipide und deren verwendung - Google Patents

Geladene lipide und deren verwendung

Info

Publication number
ATE337019T1
ATE337019T1 AT98906695T AT98906695T ATE337019T1 AT E337019 T1 ATE337019 T1 AT E337019T1 AT 98906695 T AT98906695 T AT 98906695T AT 98906695 T AT98906695 T AT 98906695T AT E337019 T1 ATE337019 T1 AT E337019T1
Authority
AT
Austria
Prior art keywords
charged lipids
compositions
drug delivery
imaging
lipids
Prior art date
Application number
AT98906695T
Other languages
English (en)
Inventor
Evan C Unger
Original Assignee
Imarx Pharmaceutical Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/823,791 external-priority patent/US6143276A/en
Priority claimed from US08/851,780 external-priority patent/US6090800A/en
Priority claimed from US08/877,826 external-priority patent/US6537246B1/en
Application filed by Imarx Pharmaceutical Corp filed Critical Imarx Pharmaceutical Corp
Application granted granted Critical
Publication of ATE337019T1 publication Critical patent/ATE337019T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
    • A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
    • A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0028—Disruption, e.g. by heat or ultrasounds, sonophysical or sonochemical activation, e.g. thermosensitive or heat-sensitive liposomes, disruption of calculi with a medicinal preparation and ultrasounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/543—Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine
    • A61K47/544—Phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T428/00—Stock material or miscellaneous articles
    • Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
    • Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
    • Y10T428/2984—Microcapsule with fluid core [includes liposome]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Acoustics & Sound (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Superconductors And Manufacturing Methods Therefor (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Fats And Perfumes (AREA)
AT98906695T 1997-03-21 1998-02-25 Geladene lipide und deren verwendung ATE337019T1 (de)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US08/823,791 US6143276A (en) 1997-03-21 1997-03-21 Methods for delivering bioactive agents to regions of elevated temperatures
US08/851,780 US6090800A (en) 1997-05-06 1997-05-06 Lipid soluble steroid prodrugs
US08/877,826 US6537246B1 (en) 1997-06-18 1997-06-18 Oxygen delivery agents and uses for the same
US08/887,215 US6028066A (en) 1997-05-06 1997-07-02 Prodrugs comprising fluorinated amphiphiles
US08/925,353 US6120751A (en) 1997-03-21 1997-09-08 Charged lipids and uses for the same

Publications (1)

Publication Number Publication Date
ATE337019T1 true ATE337019T1 (de) 2006-09-15

Family

ID=27542238

Family Applications (1)

Application Number Title Priority Date Filing Date
AT98906695T ATE337019T1 (de) 1997-03-21 1998-02-25 Geladene lipide und deren verwendung

Country Status (6)

Country Link
US (3) US6120751A (de)
EP (1) EP1037673B1 (de)
AT (1) ATE337019T1 (de)
AU (1) AU6185398A (de)
DE (1) DE69835692D1 (de)
WO (1) WO1998042383A1 (de)

Families Citing this family (490)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6743779B1 (en) * 1994-11-29 2004-06-01 Imarx Pharmaceutical Corp. Methods for delivering compounds into a cell
US6008202A (en) 1995-01-23 1999-12-28 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
FI982069A7 (fi) 1996-03-29 1998-11-10 Lawrence Berkeley Nat Laboratory NMR:n ja MRI:n tehostaminen hyperpolaroitujen jalokaasujen läsnä olles sa
JP2001507207A (ja) * 1996-05-01 2001-06-05 イマアーレクス・フアーマシユーチカル・コーポレーシヨン 化合物を細胞に送達する方法
SE9604610D0 (sv) * 1996-12-16 1996-12-16 Noviscens Ab Medical composition
US6143276A (en) * 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
GB9717542D0 (en) * 1997-08-19 1997-10-22 Nycomed Imaging As Process
US6309623B1 (en) 1997-09-29 2001-10-30 Inhale Therapeutic Systems, Inc. Stabilized preparations for use in metered dose inhalers
US6565885B1 (en) 1997-09-29 2003-05-20 Inhale Therapeutic Systems, Inc. Methods of spray drying pharmaceutical compositions
US20060165606A1 (en) 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
ES2189269T3 (es) 1997-12-03 2003-07-01 Britannia Pharmaceuticals Ltd Mejoras en medicamentos para el tratamiento del asma.
US6264991B1 (en) * 1998-08-18 2001-07-24 Southern Research Institute Compositions and methods for treating intracellular infections
US6153217A (en) * 1999-01-22 2000-11-28 Biodelivery Sciences, Inc. Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents
FR2795644B1 (fr) * 1999-07-02 2004-07-30 Air Liquide Sante Int Utilisations therapeutiques d'un melange helium/oxygene, en particulier dans le traitement de l'asthme
US6533554B1 (en) * 1999-11-01 2003-03-18 University Of Southern California Thermal transpiration pump
US7897140B2 (en) 1999-12-23 2011-03-01 Health Research, Inc. Multi DTPA conjugated tetrapyrollic compounds for phototherapeutic contrast agents
US20030170297A1 (en) * 2000-04-12 2003-09-11 Kent Jorgensen Lipid-based drug delivery systems containing phospholipase a2 degradable lipid derivatives for topical application to the skin
US8404217B2 (en) 2000-05-10 2013-03-26 Novartis Ag Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en) 2000-05-10 2011-01-18 Novartis Ag Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
DK1280520T4 (en) 2000-05-10 2018-06-25 Novartis Ag Phospholipid based powders for drug delivery
US7061237B2 (en) 2000-07-13 2006-06-13 The Regents Of The University Of California Remote NMR/MRI detection of laser polarized gases
US6652833B2 (en) * 2000-07-13 2003-11-25 The Regents Of The University Of California Functionalized active-nucleus complex sensor
AU2001294185B2 (en) * 2000-10-04 2006-12-21 Kyowa Hakko Kirin Co., Ltd. Method of coating fine particles with lipid membrane
US6849194B2 (en) 2000-11-17 2005-02-01 Pcbu Services, Inc. Methods for preparing ethers, ether compositions, fluoroether fire extinguishing systems, mixtures and methods
ES2260321T3 (es) * 2000-12-07 2006-11-01 Universiteit Utrecht Holding B.V. Composicion para el tratamiento de transtornos inflamatorios.
CA2429773A1 (en) * 2000-12-22 2002-07-04 Aspen Aerogels, Inc. Aerogel powder comprising therapeutic agents
ATE409495T1 (de) 2001-04-04 2008-10-15 Nordic Vaccine Technology As Polynukleotide-bindende komplexe die sterolen und saponine enthalten
DE10117043A1 (de) * 2001-04-05 2002-11-07 Gerhard Puetz Verfahren zur Eliminierung von potentiell toxischen und/oder schädlichen Stoffen
US20030203865A1 (en) * 2001-04-30 2003-10-30 Pierrot Harvie Lipid-comprising drug delivery complexes and methods for their production
US20030166593A1 (en) * 2001-04-30 2003-09-04 Kenneth Chien Non-viral vesicle vector for cardiac specific gene delivery
WO2003006608A2 (en) * 2001-07-10 2003-01-23 Davidson Michael N Enhancement of transfection of dna into the liver
US6796957B2 (en) * 2001-07-10 2004-09-28 Myocardial Therapeutics, Inc. Sterile aspiration/reinjection systems
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
US7125568B2 (en) * 2001-08-23 2006-10-24 Sung Michael T Lipophilic drug compositions
US6680142B2 (en) * 2001-08-24 2004-01-20 The United States Of America As Represented By The Secretary Of The Navy Bio-based microbattery and methods for fabrication of same
CA2463724A1 (en) * 2001-10-16 2003-04-24 Structural Bioinformatics Inc. Organosulfur inhibitors of tyrosine phosphatases
ES2364636T3 (es) 2001-12-19 2011-09-08 Novartis Ag Administración pulmonar de aminoglucósidos.
US20060188451A1 (en) * 2001-12-21 2006-08-24 Aspen Aerogels, Inc. Aerogel based pharmaceutical formulations
BRPI0307077A2 (pt) * 2002-01-22 2017-06-20 Biomatera Inc método para secar polímeros biodegradáveis
JP4113361B2 (ja) * 2002-02-05 2008-07-09 日立ソフトウエアエンジニアリング株式会社 複層半導体ナノ粒子の製造方法
US7700074B2 (en) * 2002-02-07 2010-04-20 Pettegrew Jay W Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism
US7407778B2 (en) * 2002-02-07 2008-08-05 Pettegrew Jay W Compounds, compositions and methods for treating neuropsychiatric disorders
JP2005524657A (ja) * 2002-02-27 2005-08-18 ファーメイン， エルティーディー． 治療剤及び他の物質を送達するための組成物、及び、前記組成物を作製し使用する方法
US20050260259A1 (en) 2004-04-23 2005-11-24 Bolotin Elijah M Compositions for treatment with glucagon-like peptide, and methods of making and using the same
US7635463B2 (en) 2002-02-27 2009-12-22 Pharmain Corporation Compositions for delivery of therapeutics and other materials
WO2003075977A2 (en) * 2002-03-05 2003-09-18 Cleveland State University Agglomerated particles for aerosol drug delivery
US20030219473A1 (en) * 2002-03-26 2003-11-27 Leila Zarif Cochleates made with purified soy phosphatidylserine
WO2003082303A1 (en) * 2002-03-29 2003-10-09 Wisconsin Alumni Research Foundation Polymeric micelle formulations of hydrophobic compounds and methods
AU2003223451A1 (en) * 2002-04-03 2003-10-20 Jackie R. See Methods for ultrasonic imaging and treating diseased tissues
US20090074847A1 (en) * 2002-04-29 2009-03-19 Bio Tesys Gmbh Transport System In Biological Systems
EP1534725A2 (de) 2002-05-16 2005-06-01 Glycomimetics, Inc. Verbindungen und verfahren zur inhibierung von selectinvermittelten funktion
US8829198B2 (en) 2007-10-31 2014-09-09 Proteotech Inc Compounds, compositions and methods for the treatment of beta-amyloid diseases and synucleinopathies
US20050152962A1 (en) * 2002-06-12 2005-07-14 Metselaar Josbert M. Composition for treatment of inflammatory disorders
CA2490692A1 (en) 2002-06-27 2004-01-08 Health Research, Inc. Fluorinated chlorin and bacteriochlorin photosensitizers for photodynamic therapy
WO2004005289A2 (en) 2002-07-02 2004-01-15 Health Research, Inc. Efficient synthesis of pyropheophorbide a and its derivatives
WO2004004636A2 (en) * 2002-07-03 2004-01-15 Glycomimetics, Inc. Compositions and methods for diagnosis and therapy of medical conditions involving angiogenesis
US20070184089A1 (en) * 2002-07-15 2007-08-09 Alcon, Inc. Non-Polymeric Lipophilic Pharmaceutical Implant Compositions for Intraocular Use
PL206594B1 (pl) * 2002-07-15 2010-08-31 Alcon Kompozycja implantu śródocznego i zastosowanie leku oftalmicznego w połączeniu z niskocząsteczkowym związkiem lipofilowym do jej wytwarzania
KR100434690B1 (ko) * 2002-07-19 2004-06-04 소광섭 생명체에 대한 자기장의 영향을 측정하는 장치 및 방법
AU2003275009A1 (en) * 2002-09-16 2004-04-30 Biotechnology Research And Development Corporation Methods for manufacturing polysaccharide derivatives
JP4886297B2 (ja) 2002-11-01 2012-02-29 バイオデリバリー サイエンシーズ インターナショナル インコーポレイティッド ジオデート送達媒体
ES2431520T3 (es) * 2003-01-25 2013-11-26 Seno Medical Instruments, Inc. Procedimiento de formación de imágenes optoacústicas de contraste elevado utilizando nanopartículas no esféricas
US8017135B1 (en) * 2003-01-31 2011-09-13 The Regents Of The University Of California Lipid-drug conjugates for local therapy of eye diseases
AU2004210221B2 (en) 2003-02-04 2008-11-20 Bracco Suisse S.A. Ultrasound contrast agents and process for the preparation thereof
JP4909071B2 (ja) * 2003-03-24 2012-04-04 プルーローメッド， インコーポレイテッド 逆感熱性ポリマーを使用する一時的な塞栓形成
JP4789208B2 (ja) * 2003-04-09 2011-10-12 バイオデリバリー サイエンシーズ インターナショナル インコーポレイティッド タンパク質発現に向けられた渦巻型組成物
WO2004091578A2 (en) * 2003-04-09 2004-10-28 Biodelivery Sciences International, Inc. Novel encochleation methods, cochleates and methods of use
WO2004099158A1 (en) * 2003-04-30 2004-11-18 Ricerca Biosciences, Llc. Monocyclic diazodioxide based bcl-2 protein antagonists
WO2004099162A1 (en) * 2003-04-30 2004-11-18 Ricerca Biosciences, Llc. Polycyclic diazodioxide-based bcl-2 protein antagonist
US20040219158A1 (en) * 2003-05-02 2004-11-04 Glycomimetics, Inc. Compositions and methods for diagnosis and therapy of medical conditions involving infection with pseudomonas bacteria
US20060142395A1 (en) * 2003-05-06 2006-06-29 University Of North Texas Health Science Center Modulation of intracellular calcium signaling by N-acylethanolamines
US20070129441A1 (en) * 2003-05-06 2007-06-07 University Of North Texas Health Science Center At Fort Worth Protection of cells from adverse external or intrinsic effects, cellular degeneration and death by n-acylethanolamines
MXPA05012281A (es) * 2003-05-14 2006-05-19 Torreypines Therapeutics Inc Compuestos y uso de los mismos en la modulacion beta amiloide.
US20040228800A1 (en) * 2003-05-15 2004-11-18 Scicotec Gmbh Non-invasive identification of patients at increased risk for myocardial infarction
US20060257842A1 (en) * 2003-05-29 2006-11-16 Pettegrew Jay W Cryopreservation media and molecules
EP1641806B1 (de) * 2003-05-29 2009-07-29 Jay W. Pettegrew Glycerophosphocholin und derivate davon zur medizinischen abbildung von neuropsychiatrischen erkrankungen
US8916598B2 (en) 2003-05-30 2014-12-23 Proteotech Inc Compounds, compositions, and methods for the treatment of β-amyloid diseases and synucleinopathies
US20100331380A1 (en) * 2009-06-29 2010-12-30 Esposito Luke A Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies
EP1633335A4 (de) * 2003-06-19 2009-08-19 Advanced Bionutrition Corp Verbesserte absorption von fettlöslichen nährstoffen
US20060239913A1 (en) * 2003-06-25 2006-10-26 Marc Port Peptide conjugate for magnetic resonance imaging
US7057100B2 (en) * 2003-06-26 2006-06-06 The J.C. Robinson Seed Co. Inbred corn line W23129
US8440225B2 (en) * 2003-08-07 2013-05-14 Ethicon, Inc. Process of making flowable hemostatic compositions and devices containing such compositions
US20060019868A1 (en) * 2004-01-30 2006-01-26 Pendharkar Sanyog M Hemostatic compositions and devices
US7927626B2 (en) * 2003-08-07 2011-04-19 Ethicon, Inc. Process of making flowable hemostatic compositions and devices containing such compositions
AU2004263136A1 (en) * 2003-08-08 2005-02-17 Barnes-Jewish Hospital Emulsion particles for imaging and therapy and methods of use thereof
JP4394916B2 (ja) * 2003-09-19 2010-01-06 独立行政法人科学技術振興機構 人工脂質二重膜の形成装置および人工脂質二重膜の形成方法、並びにその利用
US7700086B2 (en) * 2003-11-06 2010-04-20 Pluromed, Inc. Internal clamp for surgical procedures
WO2005054264A2 (en) * 2003-11-19 2005-06-16 Glycomimetics, Inc. Glycomimetic antagonists for both e- and p-selectins
EP1763533B1 (de) * 2003-11-19 2008-01-09 GlycoMimetics, Inc. Spezifischer antagonist sowohl für e- als auch p-selektine
JP5513708B2 (ja) 2003-12-22 2014-06-04 ブラッコ・シュイス・ソシエテ・アノニム 造影イメージング用の気体封入マイクロベシクル・アセンブリー
KR100638041B1 (ko) * 2003-12-24 2006-10-23 주식회사 삼양사 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법
WO2005067517A2 (en) * 2004-01-02 2005-07-28 Wisconsin Alumni Research Foundation Encapsulation of chemical compounds in fluorous-core and fluorous-inner-shell micelles formed from semifluorinated-block or fluorinated-block copolymers
US20050152844A1 (en) * 2004-01-09 2005-07-14 Barbut Denise R. Transpulmonary systemic cooling using liquid mists
WO2005074888A2 (en) * 2004-02-03 2005-08-18 Biodelivery Sciences International, Inc. Replacement enzyme cochleates
WO2005090370A1 (en) * 2004-02-05 2005-09-29 The Regents Of The University Of California Pharmacologically active agents containing esterified phosphonates and methods for use thereof
US9028829B2 (en) * 2004-02-20 2015-05-12 The Children's Hospital Of Philadelphia Uniform field magnetization and targeting of therapeutic formulations
US8562505B2 (en) 2004-02-20 2013-10-22 The Children's Hospital Of Philadelphia Uniform field magnetization and targeting of therapeutic formulations
US7846201B2 (en) * 2004-02-20 2010-12-07 The Children's Hospital Of Philadelphia Magnetically-driven biodegradable gene delivery nanoparticles formulated with surface-attached polycationic complex
US20070100457A1 (en) * 2004-03-04 2007-05-03 Hyde Edward R Jr Paramagnetic liquid interface
JP2007532573A (ja) * 2004-04-09 2007-11-15 バイオデリバリー サイエンシーズ インターナショナル インコーポレイティッド ヌクレオチド−渦巻状組成物および使用の方法
CN1976693A (zh) 2004-05-20 2007-06-06 斯克里普斯研究所 转甲状腺素蛋白的稳定
HUE037643T2 (hu) 2004-06-12 2018-09-28 Collegium Pharmaceutical Inc Visszaélésre nem alkalmas gyógyszerkészítmények
US20060135773A1 (en) * 2004-06-17 2006-06-22 Semple Joseph E Trisubstituted nitrogen modulators of tyrosine phosphatases
NZ582684A (en) 2004-06-18 2011-05-27 Ambrx Inc Use of an antibody or binding fragment thereof comprising a non naturally encoded amino acid coupled to a linker
JP2008505916A (ja) * 2004-07-09 2008-02-28 メタバシス・セラピューティクス・インコーポレイテッド チロシンホスファターゼの酸素／窒素複素環阻害剤
GB0418172D0 (en) * 2004-08-13 2004-09-15 Ic Vec Ltd Vector
CN103120799A (zh) 2004-08-18 2013-05-29 博莱科瑞士股份有限公司 用于反差成像的充气微泡组合物
EP1841749A1 (de) * 2004-09-02 2007-10-10 Metabasis Therapeutics, Inc. Thiazol- und thiadiazolderivate als inhibitoren von tyrosinphosphatasen
NZ588431A (en) 2004-09-17 2012-02-24 Whitehead Biomedical Inst Using Benzimidazole or Indole compounds with a 1,2-diazole group to Inhibit Alpha-Synuclein Toxicity
US20060067889A1 (en) * 2004-09-27 2006-03-30 Light Sciences Corporation Singlet oxygen photosensitizers activated by target binding enhancing the selectivity of targeted PDT agents
BRPI0519754A2 (pt) 2005-01-13 2009-03-10 Cinv Ag materiais compàsitos contendo nanopartÍculas de carbono
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
US20070059775A1 (en) * 2005-03-29 2007-03-15 The Trustees Of Columbia University In The City Of New York Synthesis and conjugation of iron oxide nanoparticles to antibodies for targeting specific cells using fluorescence and MR imaging techniques
US20090156545A1 (en) * 2005-04-01 2009-06-18 Hostetler Karl Y Substituted Phosphate Esters of Nucleoside Phosphonates
JP5242375B2 (ja) 2005-04-01 2013-07-24 ザ レゲントス オブ ザ ユニバーシティ オブ カリフォルニア ホスホノ−ペント−２−エン−１−イルヌクレオシド及び類似体
US8669236B2 (en) * 2005-05-12 2014-03-11 The General Hospital Corporation Biotinylated compositions
WO2006127906A1 (en) * 2005-05-25 2006-11-30 Glycomimetics, Inc. Heterobifunctional compounds for selectin inhibition
WO2007002109A2 (en) * 2005-06-20 2007-01-04 The Regents Of The University Of California Multidentate pyrone-derived chelators for medicinal imaging and chelation
US8435558B1 (en) 2005-06-28 2013-05-07 University Of South Florida Ultrasound enhancement of drug release across non-ionic surfactant membranes
US7981442B2 (en) * 2005-06-28 2011-07-19 University Of South Florida Ultrasound enhancement of drug release across non-ionic surfactant membranes
ITPD20050207A1 (it) 2005-07-07 2007-01-08 Fidia Farmaceutici Nuove composizioni farmaceutiche contenenti acido ialuronico e collagenas nel trattamento topico di ferite, ustioni ed ulcere
CA2618638C (en) * 2005-08-09 2014-03-11 Glycomimetics, Inc. Glycomimetic inhibitors of the pa-il lectin, pa-iil lectin or both the lectins from pseudomonas
LT2264043T (lt) 2005-09-02 2017-12-11 Glycomimetics, Inc. Heterobifunkciniai pan-selektino inhibitoriai
US8492428B2 (en) * 2005-09-20 2013-07-23 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
AU2006303324A1 (en) * 2005-10-18 2007-04-26 Cinvention Ag Thermoset particles and methods for production thereof
US20070140974A1 (en) * 2005-12-15 2007-06-21 General Electric Company Targeted nanoparticles for magnetic resonance imaging
AU2006330610B2 (en) 2005-12-19 2012-08-16 Pharmain Corporation Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
WO2007076160A2 (en) * 2005-12-28 2007-07-05 Acidophil Llc C-10 carbamates of taxanes
JP5424480B2 (ja) * 2006-03-13 2014-02-26 杏林製薬株式会社 Ｇｓｋ−３インヒビターとしてのアミノキノロン
JP2009531443A (ja) * 2006-03-29 2009-09-03 フォールドアールエックス ファーマシューティカルズ インコーポレーティッド α−シヌクレイン毒性の抑制
US9789161B2 (en) * 2006-04-28 2017-10-17 Warsaw Orthopedic, Inc. Methods for treating back or neck pain caused by NGF using a therapeutic agent consisting of ReN-1820, ALE-0540 and capsaicin
WO2007130748A1 (en) * 2006-05-03 2007-11-15 Discus Dental Impressions, Inc. Dental instruments having anti-microbial coating
WO2007133801A2 (en) * 2006-05-15 2007-11-22 Dmitri B Kirpotin Magnetic microparticles comprising organic substances
US20090176717A1 (en) * 2006-06-01 2009-07-09 Glycomimetics, Inc. Galactosides and thiodigalactosides as inhibitors of pa-il lectin from pseudomonas
US20100068264A1 (en) * 2006-07-12 2010-03-18 University Of South Florida Niosome-hydrogel drug delivery system
US20100016707A1 (en) 2006-08-08 2010-01-21 Keter Medical Ltd Imaging system
NZ596091A (en) 2006-08-28 2012-07-27 Jolla Inst Allergy Immunolog Antagonistic human light-specific human monoclonal antibodies
EP2066662B1 (de) 2006-09-21 2012-12-05 Kyorin Pharmaceutical Co., Ltd. Serinhydrolasehemmer
EP2074132B1 (de) 2006-10-12 2013-05-15 GlycoMimetics, Inc. Glycomimetischer ersatz für hexosen und n-acetyl-hexosamine
DE602007013440D1 (de) 2006-10-19 2011-05-05 Auspex Pharmaceuticals Inc Substituierte indole
WO2008057604A2 (en) * 2006-11-08 2008-05-15 The Regents Of The University Of California Small molecule therapeutics, syntheses of analogues and derivatives and methods of use
US9000048B2 (en) * 2006-11-28 2015-04-07 Wisconsin Alumni Research Foundation Fluoropolymer-based emulsions for the intravenous delivery of fluorinated volatile anesthetics
US20080181952A1 (en) * 2006-12-11 2008-07-31 Pluromed, Inc. Perfusive Organ Hemostasis
CA2673566A1 (en) 2006-12-19 2008-06-26 Auspex Pharmaceuticals, Inc. Preparation and utility of ccr5 inhibitors
CN101611008A (zh) * 2006-12-22 2009-12-23 恩希赛弗制药公司 C3a受体调节剂及其使用方法
US8900562B2 (en) * 2007-01-12 2014-12-02 Wisconsin Alumni Research Foundation Semi-fluorinated block copolymers for delivery of therapeutic agents
US7850382B2 (en) 2007-01-18 2010-12-14 Sanford, L.P. Valve made from two materials and writing utensil with retractable tip incorporating same
CN101646402A (zh) * 2007-01-19 2010-02-10 金文申有限公司 用粉末模塑法制成的多孔、不可降解植入物
US7488130B2 (en) 2007-02-01 2009-02-10 Sanford, L.P. Seal assembly for retractable instrument
CA2677747A1 (en) * 2007-02-09 2008-08-21 Glycomimetics, Inc. Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines
WO2008104586A2 (en) * 2007-02-28 2008-09-04 Cinvention Ag High surface cultivation system with surface increasing substrate
AU2008220793A1 (en) * 2007-02-28 2008-09-04 Cinvention Ag High surface cultivation system
WO2008104587A2 (en) * 2007-02-28 2008-09-04 Cinvention Ag High surface cultivation system with filler
WO2008104599A1 (en) * 2007-02-28 2008-09-04 Cinvention Ag High surface cultivation system bag
WO2008106167A1 (en) * 2007-02-28 2008-09-04 Conatus Pharmaceuticals, Inc. Combination therapy comprising matrix metalloproteinase inhibitors and caspase inhibitors for the treatment of liver diseases
PT2144604E (pt) 2007-02-28 2011-10-19 Conatus Pharmaceuticals Inc Métodos para o tratamento da hepatite c viral crónica utilizando ro-113-0830
US9814672B2 (en) * 2007-03-09 2017-11-14 Susan T. Laing Echogenic vehicle for clinical delivery of plasminogen activator and other fibrin-binding therapeutics to thrombi
AU2008251773A1 (en) 2007-03-15 2008-11-20 Auspex Pharmaceuticals, Inc. Deuterated venlafaxines and 0-desmetylvenlafaxines with serotoninergic and / or norepinephrinergic activity
FR2914304B1 (fr) * 2007-03-28 2012-11-16 Guerbet Sa Composes pour le diagnostic de maladies liees a l'expression de vcam.
FR2914303A1 (fr) * 2007-03-28 2008-10-03 Guerbet Sa Composes pour le diagnostic de l'apoptose.
US7892776B2 (en) 2007-05-04 2011-02-22 The Regents Of The University Of California Screening assay to identify modulators of protein kinase A
US20080287931A1 (en) * 2007-05-18 2008-11-20 Jones Dennis R Use of iontophoresis and ultrasound to deliver melanin or other chromophores for laser hair removal
BRPI0814542A2 (pt) * 2007-07-12 2014-09-30 Tragara Pharmaceuticals Inc Métodos e composições para o tratamento de câncer, tumores e desordens relacionadas a tumores
US8039442B2 (en) * 2007-07-18 2011-10-18 Glycomimetics, Inc. Compounds and methods for treatment of sickle cell disease or complications associated therewith
US7960336B2 (en) 2007-08-03 2011-06-14 Pharmain Corporation Composition for long-acting peptide analogs
US8563527B2 (en) 2007-08-20 2013-10-22 Pharmain Corporation Oligonucleotide core carrier compositions for delivery of nucleic acid-containing therapeutic agents, methods of making and using the same
EP2203458B1 (de) * 2007-09-11 2011-11-02 Kyorin Pharmaceutical Co., Ltd. Cyanoaminochinolone als gsk-3-inhibitoren
CA2699152C (en) 2007-09-12 2015-11-24 Activx Biosciences, Inc. Spirocyclic aminoquinolones as gsk-3 inhibitors
US8003621B2 (en) * 2007-09-14 2011-08-23 Nitto Denko Corporation Drug carriers
EP2192922A4 (de) 2007-09-17 2010-09-29 Univ California Auf prostatazellen in situ abzielende internalisierende humane monoklonale antikörper
WO2009042972A1 (en) * 2007-09-26 2009-04-02 Tufts University Fluorinated lipids and methods of use
WO2009043031A2 (en) * 2007-09-27 2009-04-02 Children's Medical Center Corporation Microbubbles and methods for oxygen delivery
US20090264421A1 (en) * 2007-10-05 2009-10-22 Bible Keith C Methods and Compositions for Treating Cancer
CN101917845A (zh) * 2007-11-21 2010-12-15 法马克西斯制药公司 Ssao/vap-1的卤代烯丙胺抑制剂及其用途
IL188647A0 (en) * 2008-01-08 2008-11-03 Orina Gribova Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
US20090176892A1 (en) 2008-01-09 2009-07-09 Pharmain Corporation Soluble Hydrophobic Core Carrier Compositions for Delivery of Therapeutic Agents, Methods of Making and Using the Same
WO2009111611A2 (en) * 2008-03-05 2009-09-11 Proteotech Inc. Compounds, compositions and methods for the treatment of islet amyloid polypeptide (iapp) accumulation in diabetes
PT2947072T (pt) 2008-03-17 2016-12-06 Ambit Biosciences Corp 1-(3-(6,7-dimetoxiquinazolin-4-iloxi)fenil)-3-(5-(1,1,1-trifluoro-2-metilpropan-2-il)isoxazol-3-il)ureia como modulador da cinase raf no tratamento de doenças oncológicas
US8226312B2 (en) 2008-03-28 2012-07-24 Sanford, L.P. Valve door having a force directing component and retractable instruments comprising same
WO2009126556A1 (en) 2008-04-08 2009-10-15 Glycomimetics, Inc. Pan-selectin inhibitor with enhanced pharmacokinetic activity
EP2123258A1 (de) * 2008-05-23 2009-11-25 Liplasome Pharma A/S Liposomen zur Arzneimittelverabreichung
EP2318015B1 (de) * 2008-06-13 2013-08-07 GlycoMimetics, Inc. Behandlung von blutkrebs mit ausgewählten glykomimetischen verbindungen
RU2505315C2 (ru) * 2008-07-30 2014-01-27 Нитто Денко Корпорейшн Носители лекарственных средств
US20110070154A1 (en) * 2008-08-13 2011-03-24 Hyde Roderick A Artificial cells
CN101658533A (zh) * 2008-08-29 2010-03-03 首都医科大学宣武医院 抗肿瘤药物的干细胞递送
US20100069827A1 (en) 2008-09-12 2010-03-18 Barry Neil Silberg Pre-Surgical Prophylactic Administration of Antibiotics and Therapeutic Agents
US9446227B2 (en) 2008-09-12 2016-09-20 Sonescence, Inc. Ultrasonic dispersion of compositions in tissue
US8221012B2 (en) 2008-11-07 2012-07-17 Sanford, L.P. Retractable instruments comprising a one-piece valve door actuating assembly
EP2398466B1 (de) 2008-11-24 2021-02-17 Massachusetts Institute of Technology Verfahren und zusammensetzungen zur lokalisierten nanopartikel-abgabe an tumoren
US8393814B2 (en) 2009-01-30 2013-03-12 Sanford, L.P. Retractable instrument having a two stage protraction/retraction sequence
WO2010088450A2 (en) 2009-01-30 2010-08-05 Celladon Corporation Methods for treating diseases associated with the modulation of serca
US8568793B2 (en) 2009-02-11 2013-10-29 Hope Medical Enterprises, Inc. Sodium nitrite-containing pharmaceutical compositions
PL2401267T3 (pl) 2009-02-27 2014-06-30 Ambit Biosciences Corp Pochodne chinazoliny modulujące kinazę JAK i ich zastosowanie w metodach
EP2403860B1 (de) 2009-03-04 2015-11-04 IDENIX Pharmaceuticals, Inc. Phosphothiophene und phosphothiazole als hcv polymerase inhibitoren
MX2011009413A (es) 2009-03-11 2011-10-21 Ambit Biosciences Corp Combinacion de una indazolilaminopirrolotriazina y taxano para tratamiento contra cancer.
CN102421784B (zh) * 2009-03-11 2015-09-30 杏林制药株式会社 作为gsk-3抑制剂的7-环烷基氨基喹诺酮
BRPI1013600A2 (pt) 2009-03-27 2019-09-24 Pathway Therapeutics Inc "sulfonamidas de pirimidinila e benzintoazol de 1,3,5-triazinila e seu uso em terapia de câncer"
WO2010110686A1 (en) 2009-03-27 2010-09-30 Pathway Therapeutics Limited Pyrimidinyl and 1,3,5 triazinyl benzimidazoles and their use in cancer therapy
AU2010239340B2 (en) 2009-04-22 2015-07-02 Axikin Pharmaceuticals, Inc. 2,5-disubstituted arylsulfonamide CCR3 antagonists
MX2011011139A (es) 2009-04-22 2012-01-27 Axikin Pharmaceuticals Inc Antagonistas ccr3 arisulfonamida 2, 5-disustituidos.
PE20120811A1 (es) 2009-04-22 2012-07-08 Axikin Pharmaceuticals Inc Antagonistas ccr3 arilsulfonamida
EP2424544A1 (de) * 2009-05-01 2012-03-07 GlycoMimetics, Inc. Heterobifunktionale inhibitoren von e-selectinen und cxcr4-chemokin-rezeptoren
AU2010245933B2 (en) * 2009-05-05 2016-06-16 Arbutus Biopharma Corporation Methods of delivering oligonucleotides to immune cells
US20100323018A1 (en) * 2009-06-17 2010-12-23 Massachusetts Institute Of Technology Branched DNA/RNA monomers and uses thereof
US20100324124A1 (en) * 2009-06-17 2010-12-23 Massachusetts Institute Of Technology Compositions and methods relating to DNA-based particles
WO2011003870A2 (en) 2009-07-06 2011-01-13 Creabilis S.A. Mini-pegylated corticosteroids, compositions including same, and methods of making and using same
CA2987503C (en) 2009-07-07 2019-02-26 Mei Pharma, Inc. Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy
EP2451435B2 (de) 2009-07-08 2021-12-01 Hope Medical Enterprises, Inc. d.b.a. Hope Pharmaceuticals Natriumthiosulfathaltige pharmazeutische zusammensetzungen
CN105997864A (zh) 2009-07-09 2016-10-12 奥莎迪药品管理有限公司 基质载体组合物、方法及用途
US8404728B2 (en) 2009-07-30 2013-03-26 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
CA2769652A1 (en) 2009-08-05 2011-02-10 Idenix Pharmaceuticals, Inc. Macrocyclic serine protease inhibitors useful against viral infections, particularly hcv
WO2011022473A1 (en) 2009-08-19 2011-02-24 Ambit Biosciences Corporation Biaryl compounds and methods of use thereof
TW201120037A (en) * 2009-10-26 2011-06-16 Sunesis Pharmaceuticals Inc Compounds and methods for treatment of cancer
WO2011056764A1 (en) 2009-11-05 2011-05-12 Ambit Biosciences Corp. Isotopically enriched or fluorinated imidazo[2,1-b][1,3]benzothiazoles
EP2499282B1 (de) 2009-11-09 2015-04-22 NeuroGenetic Pharmaceuticals, Inc. Gamma-sekretase-modulierende verbindungen, verfahren zu ihrer identifikation und verwendungen dafür
WO2011069002A1 (en) 2009-12-02 2011-06-09 Alquest Therapeutics, Inc. Organoselenium compounds and uses thereof
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US20110144216A1 (en) * 2009-12-16 2011-06-16 Honeywell International Inc. Compositions and uses of cis-1,1,1,4,4,4-hexafluoro-2-butene
AR079528A1 (es) 2009-12-18 2012-02-01 Idenix Pharmaceuticals Inc Inhibidores de arileno o heteroarileno 5,5-fusionado del virus de la hepatitis c
US8710092B2 (en) * 2009-12-23 2014-04-29 Map Pharmaceuticals, Inc. Substituted indolo 4,3 FG quinolines useful for treating migraine
WO2011094890A1 (en) 2010-02-02 2011-08-11 Argusina Inc. Phenylalanine derivatives and their use as non-peptide glp-1 receptor modulators
AU2011223873B2 (en) 2010-03-02 2015-06-25 Axikin Pharmaceuticals, Inc. Isotopically enriched arylsulfonamide CCR3 antagonists
WO2011112689A2 (en) 2010-03-11 2011-09-15 Ambit Biosciences Corp. Saltz of an indazolylpyrrolotriazine
EP2547655B1 (de) 2010-03-17 2016-03-09 Axikin Pharmaceuticals, Inc. Arylsulfonamid-ccr-3-antagonisten
WO2011115684A2 (en) * 2010-03-19 2011-09-22 Massachusetts Institute Of Technology Lipid vesicle compositions and methods of use
US9149432B2 (en) 2010-03-19 2015-10-06 Massachusetts Institute Of Technology Lipid vesicle compositions and methods of use
US20110229556A1 (en) * 2010-03-19 2011-09-22 Massachusetts Institute Of Technology Lipid-coated polymer particles for immune stimulation
WO2011150198A1 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl urea compounds and methods of use thereof
WO2011150201A2 (en) 2010-05-27 2011-12-01 Ambit Biosciences Corporation Azolyl amide compounds and methods of use thereof
MX342465B (es) 2010-06-01 2016-09-30 Biotheryx Inc * Metodos para tratar enfermedades hematologicas usando 6-ciclohexil-1-hidroxi-4-metil-2(1h)-piridona.
CN104926722A (zh) 2010-06-01 2015-09-23 拜欧赛里克斯公司 羟基吡啶酮衍生物、其药物组合物及其用于治疗增生性疾病的治疗用途
SG186229A1 (en) 2010-06-07 2013-01-30 Novomedix Llc Furanyl compounds and the use thereof
WO2012012370A1 (en) 2010-07-19 2012-01-26 Summa Health System Vitamin c and chromium-free vitamin k, and compositions thereof for treating an nfkb-mediated condition or disease
US20130317045A1 (en) 2010-09-01 2013-11-28 Ambit Biosciences Corporation Thienopyridine and thienopyrimidine compounds and methods of use thereof
CN103298805A (zh) 2010-09-01 2013-09-11 埃姆比特生物科学公司 喹唑啉化合物及其使用方法
EP2611794A1 (de) 2010-09-01 2013-07-10 Ambit Biosciences Corporation 4--azolylaminochinazolinderivate und verwendungsverfahren dafür
WO2012030910A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation 2-cycloquinazoline derivatives and methods of use thereof
EP2611809A1 (de) 2010-09-01 2013-07-10 Ambit Biosciences Corporation Azolopyridin- und azolopyrimidinverbindungen sowie verfahren zu ihrer verwendung
US20130225578A1 (en) 2010-09-01 2013-08-29 Ambit Biosciences Corporation 7-cyclylquinazoline derivatives and methods of use thereof
WO2012030918A1 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Adenosine a3 receptor modulating compounds and methods of use thereof
WO2012030944A2 (en) 2010-09-01 2012-03-08 Ambit Biosciences Corporation Quinoline and isoquinoline compounds and methods of use thereof
ES2581840T3 (es) 2010-09-01 2016-09-07 Ambit Biosciences Corporation Pirazolilaminoquinazolina ópticamente activa y composiciones farmacéuticas y métodos de uso de la misma
EP2611792B1 (de) 2010-09-01 2017-02-01 Ambit Biosciences Corporation Hydrobromid salze einer pyrazolylaminoquinazolin
WO2012037034A1 (en) 2010-09-14 2012-03-22 Glycomimetics, Inc. E-selectin antagonists
WO2012044641A1 (en) 2010-09-29 2012-04-05 Pathway Therapeutics Inc. 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
CA2814011A1 (en) 2010-10-11 2012-04-19 Axikin Pharmaceuticals, Inc. Salts of arylsulfonamide ccr3 antagonists
CA2819859A1 (en) 2010-12-06 2012-06-14 Follica, Inc. Methods for treating baldness and promoting hair growth
WO2012080050A1 (en) 2010-12-14 2012-06-21 F. Hoffmann-La Roche Ag Solid forms of a phenoxybenzenesulfonyl compound
US8808740B2 (en) 2010-12-22 2014-08-19 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
DK2668210T3 (da) 2011-01-26 2020-08-24 Celldex Therapeutics Inc Anti-kit antistoffer og anvendelser deraf
EP2670396A1 (de) 2011-01-31 2013-12-11 Celgene Corporation Pharmazeutische zusammensetzungen aus cytidinanaloga und anwendungsverfahren dafür
TW201309690A (zh) 2011-02-10 2013-03-01 Idenix Pharmaceuticals Inc 巨環絲胺酸蛋白酶抑制劑，其醫藥組合物及其於治療ｈｃｖ感染之用途
CN105388287A (zh) 2011-03-11 2016-03-09 内布拉斯加大学董事委员会 冠状动脉疾病的生物标志物
JP2014509648A (ja) 2011-03-28 2014-04-21 メイ プハルマ，インコーポレーテッド （α−置換シクロアルキルアミノ及びヘテロシクリルアミノ）ピリミジニル及び１，３，５−トリアジニルベンズイミダゾール、その医薬組成物、並びに増殖性疾患の治療におけるそれらの使用
BR112013024907A2 (pt) 2011-03-28 2016-12-20 Mei Pharma Inc composto, composição farmacêutica, método para o tratamento, prevenção ou atenuação de um ou mais sintomas de um distúrbio, doença ou condição mediada por pi3k em um sujeito, método para modular a atividade enzimática de pi3k
WO2012135166A1 (en) 2011-03-28 2012-10-04 Pathway Therapeutics Inc. (fused ring arylamino and heterocyclylamino) pyrimidynyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases
US20120252721A1 (en) 2011-03-31 2012-10-04 Idenix Pharmaceuticals, Inc. Methods for treating drug-resistant hepatitis c virus infection with a 5,5-fused arylene or heteroarylene hepatitis c virus inhibitor
MX2013015373A (es) 2011-06-23 2014-02-11 Map Pharmaceuticals Inc Nuevos analogos de fluoroergolina.
WO2013037482A1 (en) 2011-09-15 2013-03-21 Phenex Pharmaceuticals Ag Farnesoid x receptor agonists for cancer treatment and prevention
SI2766359T1 (sl) 2011-10-14 2016-09-30 Ambit Biosciences Corporation Heterociklične spojine in njihova uporaba kot modulatorjev receptorja tirozin kinaze tipa III
SG10201509139QA (en) 2011-12-19 2015-12-30 Map Pharmaceuticals Inc Novel iso-ergoline derivatives
EP2793583A4 (de) 2011-12-21 2015-08-12 Map Pharmaceuticals Inc Neuartige neuromodulatorische verbindungen
EP3296310A1 (de) 2011-12-22 2018-03-21 GlycoMimetics, Inc. E-selectin-antagonisten-verbindungen, zusammensetzungen daraus und verfahren zur verwendung
US9611253B2 (en) 2012-02-29 2017-04-04 Ambit Biosciences Corporation Solid forms comprising optically active pyrazolylaminoquinazoline, compositions thereof, and uses therewith
CN104302640A (zh) 2012-03-16 2015-01-21 埃克希金医药品有限公司 3,5-二氨基吡唑激酶抑制剂
WO2013151682A1 (en) 2012-04-06 2013-10-10 Children's Medical Center Corporation Process for forming microbubbles with high oxygen content and uses thereof
CA3086105A1 (en) 2012-05-02 2013-11-07 Boehringer Ingelheim International Gmbh Substituted 3-haloallylamine inhibitors of ssao and uses thereof
US9320750B2 (en) * 2012-05-11 2016-04-26 Massachusetts Institute Of Technology Compositions and methods of treatment of drug resistant cancers
US9713459B2 (en) * 2012-06-11 2017-07-25 The Regents Of The University Of California Method and system for in vivo hydrogen peroxide detection with ultrasound
US9732038B2 (en) 2012-06-14 2017-08-15 Mayo Foundation For Medical Education And Research Pyrazole derivatives as inhibitors of STAT3
US9012640B2 (en) 2012-06-22 2015-04-21 Map Pharmaceuticals, Inc. Cabergoline derivatives
RU2681730C2 (ru) 2012-07-25 2019-03-12 Селлдекс Терапьютикс Инк. Антитела против kit и их применения
ES2688397T3 (es) 2012-07-30 2018-11-02 Matinas Biopharma Nanotechnologies, Inc. Cocleatos hechos con fosfatidilserina de soja
US9074186B2 (en) 2012-08-15 2015-07-07 Boston Medical Center Corporation Production of red blood cells and platelets from stem cells
US9655977B2 (en) 2012-08-31 2017-05-23 The General Hospital Corporation Biotin complexes for treatment and diagnosis of alzheimer's disease
AU2013312420A1 (en) 2012-09-07 2015-02-26 Axikin Pharmaceuticals, Inc. Isotopically enriched arylsulfonamide CCR3 antagonists
WO2014055647A1 (en) 2012-10-03 2014-04-10 Mei Pharma, Inc. (sulfinyl and sulfonyl benzimidazolyl) pyrimidines and triazines, pharmaceutical compositions thereof, and their use for treating proliferative diseases
WO2014074765A2 (en) 2012-11-08 2014-05-15 Summa Health System Vitamin c, vitamin k, a polyphenol, and combinations thereof for wound healing
JP6313779B2 (ja) 2012-11-30 2018-04-18 ノボメディックス, エルエルシーNovomedix, Llc 置換ビアリールスルホンアミドおよびその利用
US9867841B2 (en) 2012-12-07 2018-01-16 Glycomimetics, Inc. Compounds, compositions and methods using E-selectin antagonists for mobilization of hematopoietic cells
US9169214B2 (en) 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
AU2013361340A1 (en) 2012-12-21 2015-07-09 Map Pharmaceuticals, Inc. Novel methysergide derivatives
AU2014205324A1 (en) 2013-01-11 2015-07-30 Mayo Foundation For Medical Education And Research Vitamins C and K for treating polycystic diseases
US9101745B2 (en) 2013-03-14 2015-08-11 Sonogene Llc Sonochemical induction of ABCA1 expression and compositions therefor
US10577554B2 (en) 2013-03-15 2020-03-03 Children's Medical Center Corporation Gas-filled stabilized particles and methods of use
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
EP3003390B1 (de) 2013-06-06 2021-07-07 Pierre Fabre Médicament Anti-c10orf54-antikörper und verwendungen davon
KR20160055170A (ko) 2013-08-30 2016-05-17 암비트 바이오사이언시즈 코포레이션 바이아릴 아세트아미드 화합물 및 이의 사용 방법
NZ631142A (en) 2013-09-18 2016-03-31 Axikin Pharmaceuticals Inc Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
EP3046924A1 (de) 2013-09-20 2016-07-27 IDENIX Pharmaceuticals, Inc. Inhibitoren des hepatitis-c-virus
EP4043036A1 (de) 2013-09-27 2022-08-17 Massachusetts Institute of Technology Trägerfreie biologisch aktive proteinnanostrukturen
US10272117B2 (en) 2014-02-24 2019-04-30 Celgene Corporation Methods of using an activator of cereblon for neural cell expansion and the treatment of central nervous system disorders
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US20170066779A1 (en) 2014-03-05 2017-03-09 Idenix Pharmaceuticals Llc Solid forms of a flaviviridae virus inhibitor compound and salts thereof
KR102409739B1 (ko) 2014-03-20 2022-06-17 카펠라 테라퓨틱스, 인크. 암 치료용의 ｅｒｂｂ 티로신 키나제 억제제로서의 벤즈이미다졸 유도체
TWI807150B (zh) 2014-03-20 2023-07-01 美商卡佩拉醫療公司 苯并咪唑衍生物及其醫藥組合物及使用方法
US9522114B1 (en) 2014-03-27 2016-12-20 University Of South Florida Enhanced targeted drug delivery system via chitosan hydrogel and chlorotoxin
WO2015175381A1 (en) 2014-05-12 2015-11-19 Conatus Pharmaceuticals, Inc. Treatment of the complications of chronic liver disease with caspase inhibitors
PL3148579T3 (pl) 2014-05-28 2021-07-19 Agenus Inc. Przeciwciała anty-gitr i sposoby ich zastosowania
WO2015187968A1 (en) 2014-06-04 2015-12-10 Sonescence, Inc. Systems and methods for therapeutic agent delivery
WO2015195474A1 (en) 2014-06-18 2015-12-23 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating inflammatory, neurodegenerative, or immune-mediated diseases
US9499514B2 (en) 2014-07-11 2016-11-22 Celgene Corporation Antiproliferative compounds and methods of use thereof
JP6543342B2 (ja) 2014-08-14 2019-07-10 アルハマドシャー，マモウン，エム． 血清半減期を延長するための、調節可能リンカーを介した薬学的活性剤とトランスサイレチンリガンドのコンジュゲーション
SG10201902137PA (en) 2014-09-12 2019-04-29 Tobira Therapeutics Inc Cenicriviroc combination therapy for the treatment of fibrosis
WO2016065264A1 (en) 2014-10-24 2016-04-28 Biogen Ma Inc. Diterpenoid derivatives and methods of use thereof
ES2754549T3 (es) 2014-12-03 2020-04-20 Glycomimetics Inc Inhibidores heterobifuncionales de E-selectinas y receptores de quimioquinas CXCR4
SI3333191T1 (sl) 2014-12-11 2021-03-31 Pierre Fabre Medicament Proti C10ORF54 protitelesa in uporaba le-teh
CA2972048C (en) 2014-12-22 2023-03-07 The Rockefeller University Anti-mertk agonistic antibodies and uses thereof
MY191736A (en) 2014-12-23 2022-07-13 Axikin Pharmaceuticals Inc 3,5-diaminopyrazole kinase inhibitors
US9657020B2 (en) 2015-01-20 2017-05-23 Xoc Pharmaceuticals, Inc. Ergoline compounds and uses thereof
BR112017015510A2 (pt) 2015-01-20 2018-01-30 Xoc Pharmaceuticals Inc composto de fórmula estrutural (i), método de tratamento e/ou prevenção, método de agonização do receptor d2 em um indivíduo, método de antagonização do receptor d3 em um indivíduo, método de agonização do receptor 5-ht1d em um indivíduo, método de agonização do receptor 5-ht1a em um indivíduo, método de agonização seletiva do receptor 5-ht1d em vez do receptor 5-ht1b em um indivíduo, método de agonização seletiva do re-ceptor 5-ht2c em vez do receptor 5-ht2a ou 5-ht2b em um indivíduo, método de agonização do receptor 5-ht2c em um indivíduo, método de fornecimento de atividade antagonista funcional no receptor 5-ht2b ou receptor 5-ht7, e, método de fornecimento de atividade antagonista funcional nos receptores adrenérgicos em um indivíduo
KR101987994B1 (ko) 2015-01-28 2019-06-11 제이엔 테라퓨틱스 치환된 이미다조[1,2-a]피리딘-2-일아민 화합물, 및 약학 조성물 및 이의 사용 방법
FI3265123T3 (fi) 2015-03-03 2023-01-31 Vasta-aineita, käyttöjä & menetelmiä
HUE050750T2 (hu) 2015-05-29 2021-01-28 Agenus Inc CTLA-4 elleni antitestek és eljárások alkalmazásukra
US11207054B2 (en) 2015-06-19 2021-12-28 Novasignal Corp. Transcranial doppler probe
MY189806A (en) 2015-06-23 2022-03-08 Neurocrine Biosciences Inc Vmat2 inhibitors for treating neurological diseases or disorders
JP6887685B2 (ja) 2015-08-12 2021-06-16 マサチューセッツ インスティテュート オブ テクノロジー ナノ粒子の細胞表面共役
CN114605548A (zh) 2015-09-01 2022-06-10 艾吉纳斯公司 抗-pd-1抗体及其使用方法
US10065952B2 (en) 2015-10-30 2018-09-04 Neurocrine Biosciences, Inc. Valbenazine salts and polymorphs thereof
WO2017079566A1 (en) 2015-11-05 2017-05-11 Conatus Pharmaceuticals, Inc. Caspase inhibitors for use in the treatment of liver cancer
US11474102B2 (en) * 2015-11-23 2022-10-18 Massachusetts Institute Of Technology Protein corona phase molecular recognition
ES2975747T3 (es) 2015-11-30 2024-07-12 Univ California Administración de carga útil específica de tumor y activación inmunitaria utilizando un anticuerpo humano que se dirige a un antígeno de superficie celular de tumor altamente específico
US10112924B2 (en) 2015-12-02 2018-10-30 Astraea Therapeutics, Inc. Piperdinyl nociceptin receptor compounds
EP3383390A4 (de) 2015-12-02 2019-11-20 Astraea Therapeutics, LLC Piperidinyl-nociceptin-rezeptorverbindungen
CN108925135B (zh) 2015-12-23 2025-09-19 纽罗克里生物科学有限公司 制备(S)-(2R,3R,11bR)-3-异丁基-9,10-二甲氧基-2,3,4,6,7,11b-六氢-1H-吡啶并[2,1-a]异喹啉-2-基2-氨基-3-甲基丁酸酯二(4-甲基苯磺酸盐)的合成方法
JP2019500397A (ja) 2015-12-31 2019-01-10 クオナトウス ファーマシューティカルズ，インコーポレイテッド カスパーゼ阻害剤を肝疾患の治療に使用する方法
CN108778140A (zh) 2016-01-05 2018-11-09 神经系统分析公司 用于确定临床指征的系统和方法
US11589836B2 (en) 2016-01-05 2023-02-28 Novasignal Corp. Systems and methods for detecting neurological conditions
CN108778141A (zh) 2016-01-05 2018-11-09 神经系统分析公司 集成化探针结构
BR112018013761A2 (pt) 2016-01-08 2018-12-11 Celgene Corp compostos antiproliferativos e suas composições farmacêuticas e usos
CN108712904B (zh) 2016-01-08 2022-08-02 细胞基因公司 2-(4-氯苯基)-n-((2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚啉-5-基)甲基)-2,2-二氟乙酰胺的固体形式以及其药物组合物和用途
JP2019502727A (ja) 2016-01-22 2019-01-31 グリコミメティクス， インコーポレイテッド Ｐａ−ｉｌおよび／またはｐａ−ｉｉｌレクチンの糖模倣体阻害剤
US11291678B2 (en) 2016-03-02 2022-04-05 Glycomimetics, Inc Methods for the treatment and/or prevention of cardiovascular disease by inhibition of E-selectin
WO2017151836A1 (en) 2016-03-04 2017-09-08 East Carolina University J-series prostaglandin-ethanolamides as novel therapeutics for skin and/or oral disorders
WO2017156191A1 (en) 2016-03-08 2017-09-14 Los Gatos Pharmaceuticals, Inc. Composite nanoparticles and uses thereof
EP3426352A4 (de) 2016-03-08 2019-11-13 Los Gatos Pharmaceuticals, Inc. Camptothecin-derivate und verwendungen davon
WO2017180589A1 (en) 2016-04-11 2017-10-19 Auspex Pharmaceuticals, Inc. Deuterated ketamine derivatives
WO2017180794A1 (en) 2016-04-13 2017-10-19 Skyline Antiinfectives, Inc. Deuterated o-sulfated beta-lactam hydroxamic acids and deuterated n-sulfated beta-lactams
ES2939373T3 (es) 2016-05-13 2023-04-21 Pasteur Institut Inhibición de los receptores de acetilcolina nicotínicos beta-2 para tratar la patología de la enfermedad de Alzheimer
TWI753910B (zh) 2016-05-16 2022-02-01 美商拜歐斯瑞克斯公司 吡啶硫酮、其醫藥組合物及其治療增生性、炎性、神經退化性或免疫介導疾病之治療用途
CN109476751B (zh) 2016-05-27 2024-04-19 艾吉纳斯公司 抗tim-3抗体及其使用方法
US11472856B2 (en) 2016-06-13 2022-10-18 Torque Therapeutics, Inc. Methods and compositions for promoting immune cell function
WO2017222575A1 (en) 2016-06-23 2017-12-28 Collegium Pharmaceutical, Inc. Process of making more stable abuse-deterrent oral formulations
MA45602A (fr) 2016-07-08 2019-05-15 Staten Biotechnology B V Anticorps anti-apoc3 et leurs méthodes d'utilisation
WO2018031445A1 (en) 2016-08-08 2018-02-15 Glycomimetics, Inc. Combination of t-cell checkpoint inhibitors with inhibitors of e-selectin or cxcr4, or with heterobifunctional inhibitors of both e-selectin and cxcr4
WO2018035281A1 (en) 2016-08-17 2018-02-22 North Carolina State University Northern-southern route to synthesis of bacteriochlorins
WO2018053460A1 (en) * 2016-09-19 2018-03-22 The Regents Of The University Of California Paramagnetic polymers
MA46285A (fr) 2016-09-19 2019-07-31 Mei Pharma Inc Polythérapie
CA3037850A1 (en) 2016-10-07 2018-04-12 Glycomimetics, Inc. Highly potent multimeric e-selectin antagonists
WO2018071500A1 (en) 2016-10-11 2018-04-19 Agenus Inc. Anti-lag-3 antibodies and methods of use thereof
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
KR102431830B1 (ko) 2016-11-07 2022-08-16 주식회사 뉴라클사이언스 서열 유사성을 가진 항-패밀리 19, 멤버 a5 항체 및 그것의 사용 방법
WO2018089692A1 (en) 2016-11-09 2018-05-17 Phloronol, Inc. Eckol derivatives, methods of synthesis and uses thereof
CN110167542A (zh) 2016-11-09 2019-08-23 诺沃梅迪科斯有限公司 1,1-二甲双胍的亚硝酸盐、药物组合物和使用方法
EP3538551A4 (de) 2016-11-10 2020-11-11 Fortis Therapeutics, Inc. Cd46-specifische effektorzellen und verwendungen davon
WO2018102252A1 (en) 2016-11-30 2018-06-07 North Carolina State University Methods for making bacteriochlorin macrocycles comprising an annulated isocyclic ring and related compounds
WO2018102455A1 (en) 2016-12-01 2018-06-07 Ignyta, Inc. Methods for the treatment of cancer
EP3548027A1 (de) 2016-12-02 2019-10-09 Neurocrine Biosciences, Inc. Verwendung von valbenazin zur behandlung von schizophrenie oder schizoaffektiver störung
KR102603681B1 (ko) 2016-12-07 2023-11-17 아게누스 인코포레이티드 항체 및 이의 사용방법
EA201991383A1 (ru) 2016-12-07 2019-12-30 Эйдженус Инк. Антитела против ctla-4 и способы их применения
EA202090676A1 (ru) 2017-01-27 2021-10-08 Нейрокрин Байосайенсиз, Инк. Способы введения некоторых vmat2-ингибиторов
JP7307681B2 (ja) 2017-02-17 2023-07-12 カムリス インターナショナル インコーポレイテッド 汎用性抗毒素
NZ755597A (en) 2017-02-17 2023-06-30 Eidos Therapeutics Inc Processes for preparing ag-10, its intermediates, and salts thereof
WO2018160752A1 (en) 2017-02-28 2018-09-07 Children's Medical Center Corporation Stimuli-responsive particles encapsulating a gas and methods of use
WO2018164996A1 (en) 2017-03-06 2018-09-13 Neurocrine Biosciences, Inc. Dosing regimen for valbenazine
CA3054605A1 (en) 2017-03-15 2018-09-20 Glycomimetics, Inc. Galactopyranosyl-cyclohexyl derivatives as e-selectin antagonists
WO2018183182A1 (en) 2017-03-27 2018-10-04 Celgene Corporation Methods and compositions for reduction of immunogenicity
TWI842672B (zh) 2017-04-13 2024-05-21 美商艾吉納斯公司 抗ｃｄ１３７抗體及其使用方法
JP2020517242A (ja) 2017-04-21 2020-06-18 スターテン・バイオテクノロジー・ベー・フェー 抗ＡｐｏＣ３抗体およびその使用方法
US20200179352A1 (en) 2017-04-26 2020-06-11 Neurocrine Biosciences, Inc. Use of valbenazine for treating levodopa-induced dyskinesia
TW202402800A (zh) 2017-05-01 2024-01-16 美商艾吉納斯公司 抗ｔｉｇｉｔ抗體類和使用彼等之方法
JOP20190219A1 (ar) 2017-05-09 2019-09-22 Cardix Therapeutics LLC تركيبات صيدلانية وطرق لعلاج أمراض القلب والأوعية الدموية
US10085999B1 (en) 2017-05-10 2018-10-02 Arixa Pharmaceuticals, Inc. Beta-lactamase inhibitors and uses thereof
WO2018223065A1 (en) 2017-06-01 2018-12-06 Xoc Pharmaceuticals, Inc. Ergoline derivatives for use in medicine
EP3645563A4 (de) 2017-06-27 2021-03-17 Neuracle Science Co., Ltd Anti-fam19a5-antikörper und verwendungen davon
KR20220031738A (ko) 2017-06-27 2022-03-11 주식회사 뉴라클사이언스 암 치료를 위한 항-fam19a5 항체의 용도
WO2019003159A1 (en) 2017-06-27 2019-01-03 Neuracle Science Co., Ltd. USE OF ANTI-FAM19A5 ANTIBODIES FOR THE TREATMENT OF FIBROSIS
US11746149B2 (en) 2017-06-27 2023-09-05 Neuracle Science Co., Ltd. Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment of glaucoma
EP3675866B1 (de) 2017-09-01 2023-08-02 East Carolina University Ex vivo verfahren zur aktivierung von immunzellen
KR20210032924A (ko) 2017-09-05 2021-03-25 토크 테라퓨틱스, 인코포레이티드 치료용 단백질 조성물 및 그의 제조 및 사용 방법
IL273300B2 (en) 2017-09-21 2024-06-01 Neurocrine Biosciences Inc High dose valbenazine formulation and related preparations, methods and kits
EP3692171A4 (de) 2017-10-02 2021-06-23 Neuracle Science Co., Ltd Verwendung einer anti-familie mit sequenzähnlichkeit 19, element-a5-antikörper zur behandlung und diagnose von gemütsstörungen
EP3691658A4 (de) 2017-10-04 2021-06-23 The Regents of The University of California Immunmodulatorische oligosaccharide
KR20200066661A (ko) 2017-10-10 2020-06-10 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
KR20250070134A (ko) 2017-10-10 2025-05-20 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
MA50516A (fr) 2017-10-31 2020-09-09 Staten Biotechnology B V Anticorps anti-apoc3 et leurs procédés d'utilisation
EP3717013A1 (de) 2017-11-30 2020-10-07 GlycoMimetics, Inc. Verfahren zur mobilisierung von knochenmarkinfiltrierenden lymphozyten und deren verwendung
CA3085356A1 (en) 2017-12-29 2019-07-04 Glycomimetics, Inc. Heterobifunctional inhibitors of e-selectin and galectin-3
US20210052529A1 (en) 2018-01-10 2021-02-25 Cura Therapeutics, Llc Pharmaceutical compositions comprising dicarboxylic acids and their therapeutic applications
JP7395480B2 (ja) 2018-01-10 2023-12-11 クラ セラピューティクス， エルエルシー フェニルスルホンアミドを含む薬学的組成物、及びそれらの治療的適用
KR20200128025A (ko) 2018-03-05 2020-11-11 글리코미메틱스, 인크. 급성 골수성 백혈병 및 관련 병태의 치료 방법
SG11202009073WA (en) 2018-03-23 2020-10-29 Eidos Therapeutics Inc Methods of treating ttr amyloidosis using ag10
AU2019259798A1 (en) 2018-04-24 2020-11-12 Neuracle Science Co., Ltd. Use of anti-family with sequence similarity 19, member A5 antibodies for the treatment of neuropathic pain
BR112020022669A2 (pt) 2018-05-08 2021-02-17 Neuracle Science Co., Ltd distribuição de vírus adenoassociado (aav) de anticorpos anti-fam19a5
CN112119091B (zh) 2018-05-10 2025-01-03 纽洛可科学有限公司 抗序列相似家族19成员a5的抗体及其使用方法
TW202011963A (zh) 2018-06-14 2020-04-01 美商紐羅克里生物科學有限公司 Vmat2抑制劑化合物、組合物及其相關方法
WO2020006341A1 (en) 2018-06-29 2020-01-02 Conatus Pharmaceuticals, Inc. (s)-3-(2-(4-(benzyl)-3-oxopiperazin-1-yl)acetamido)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid derivatives and related compounds as caspase inhibitors for treating cardiovascular diseases
CN112740043A (zh) 2018-07-20 2021-04-30 皮埃尔法布雷医药公司 Vista受体
KR20210044817A (ko) 2018-08-15 2021-04-23 뉴로크린 바이오사이언시즈 인코퍼레이티드 특정 vmat2 억제제의 투여 방법
MA53238A (fr) 2018-08-17 2022-04-13 Eidos Therapeutics Inc Formules d'ag10
MA53811A (fr) 2018-10-03 2022-03-16 Staten Biotechnology B V Anticorps spécifiques à l'apoc3 humaine et du cynomolgus et procédés pour leur utilisation
CN119185536A (zh) 2018-10-16 2024-12-27 纽洛可科学有限公司 抗fam19a5抗体的用途
AU2019379325B2 (en) 2018-11-16 2025-04-24 Genexine, Inc. Method of treating a tumor with a combination of IL-7 protein and an immune checkpoint inhibitor
KR20200071198A (ko) 2018-12-10 2020-06-19 네오이뮨텍, 인코퍼레이티드 Nrf2 발현 조절 기반 T 세포 항암면역치료법
WO2020132071A1 (en) 2018-12-19 2020-06-25 Shy Therapeutics. Llc Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and f1brotic disease
US11845771B2 (en) 2018-12-27 2023-12-19 Glycomimetics, Inc. Heterobifunctional inhibitors of E-selectin and galectin-3
US12247070B2 (en) 2018-12-27 2025-03-11 Neuracle Science Co., Ltd. Use of anti-FAM19A5 antibodies for treating atherosclerosis
EP3906260A4 (de) 2019-01-02 2022-08-31 Neuracle Science Co., Ltd Anti-familie mit sequenzähnlichkeit 19, element a5-antikörper und verfahren zur verwendung davon
CN113874080B (zh) 2019-02-06 2024-09-27 戴斯阿尔法公司 Il-17a调节剂及其用途
EP3930847B1 (de) 2019-02-26 2024-02-14 Inspirna, Inc. Anti-mertk-antikörper mit hoher affinität und ihre verwendung
EP3935042B1 (de) 2019-03-07 2024-08-28 NOBO Medicine Inc. Caspase-inhibitoren und verfahren zur verwendung davon
WO2020198646A1 (en) * 2019-03-27 2020-10-01 The Texas A&M University System Intracellular delivery and mitochondrial targeting by fluorination
CA3138406A1 (en) 2019-05-20 2020-11-26 Christopher J. MACNEVIN Narrow emission dyes, compositions comprising same, and methods for making and using same
JP7754724B2 (ja) 2019-05-20 2025-10-15 ニルバナ サイエンシーズ インク． 発光波長の範囲が狭い発光染料、それを含む組成物及びそれを製造及び使用する方法
EP3996813A1 (de) 2019-07-11 2022-05-18 Cura Therapeutics, LLC Phenylverbindungen und pharmazeutische zusammensetzungen davon sowie deren therapeutische anwendungen
EP3997068A1 (de) 2019-07-11 2022-05-18 Cura Therapeutics, LLC Sulfonverbindungen und pharmazeutische zusammensetzungen daraus sowie ihre therapeutischen anwendungen zur behandlung von neurodegenerativen erkrankungen
US10940141B1 (en) 2019-08-23 2021-03-09 Neurocrine Biosciences, Inc. Methods for the administration of certain VMAT2 inhibitors
CN114585644A (zh) 2019-08-30 2022-06-03 艾吉纳斯公司 抗cd96抗体及其使用方法
BR112022004802A2 (pt) 2019-09-16 2022-08-23 Dice Alpha Inc Moduladores de il-17a e usos dos mesmos
KR20220150274A (ko) 2020-01-13 2022-11-10 네오이뮨텍, 인코퍼레이티드 Il-7 단백질과 이중특이적 항체의 조합물을 사용한 종양의 치료 방법
WO2021151001A1 (en) 2020-01-22 2021-07-29 Outpace Bio, Inc. Chimeric polypeptides
TW202136318A (zh) 2020-01-28 2021-10-01 美商建南德克公司 用於治療癌症的 IL15/IL15R α 異二聚體 Fc 融合蛋白質
AU2021217373A1 (en) 2020-02-05 2022-08-04 Neoimmunetech, Inc. Method of treating a solid tumor with a combination of an IL-7 protein and CAR-bearing immune cells
WO2021242970A1 (en) 2020-05-29 2021-12-02 Boulder Bioscience Llc Methods for improved endovascular thrombectomy using 3,3'-diindolylmethane
WO2021257828A1 (en) 2020-06-18 2021-12-23 Shy Therapeutics, Llc Substituted thienopyrimidines that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
WO2022006228A1 (en) 2020-06-30 2022-01-06 Prosetta Biosciences, Inc. Isoquinoline derivatives, methods of synthesis and uses thereof
EP4192511A1 (de) 2020-08-07 2023-06-14 Fortis Therapeutics, Inc. Gegen cd46 gerichtete immunkonjugate und verfahren zur verwendung davon
US20240025863A1 (en) 2020-09-16 2024-01-25 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2022087335A1 (en) 2020-10-23 2022-04-28 Biotheryx, Inc. Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2022094475A1 (en) 2020-11-02 2022-05-05 Neoimmunetech, Inc. Use of interleukin-7 for the treatment of coronavirus
JP2023549112A (ja) 2020-11-05 2023-11-22 ネオイミューンテック， インコーポレイテッド Ｉｌ－７タンパク質とヌクレオチドワクチンの組み合わせで腫瘍を治療する方法
JP2024500377A (ja) 2020-12-14 2024-01-09 バイオセリックス， インコーポレイテッド Ｐｄｅ４分解剤、医薬組成物、及び治療的応用
CN114762679B (zh) * 2021-01-13 2023-04-07 上海交通大学医学院 一种纳米复合物及其制备方法和用途
US20240309015A1 (en) 2021-01-27 2024-09-19 Shy Therapeutics, Llc Methods for the Treatment of Fibrotic Disease
EP4284377A1 (de) 2021-01-27 2023-12-06 Shy Therapeutics LLC Verfahren zur behandlung von fibrotischen erkrankungen
WO2022192545A1 (en) 2021-03-10 2022-09-15 Dice Molecules Sv, Inc. Alpha v beta 6 and alpha v beta 1 integrin inhibitors and uses thereof
EP4326721A1 (de) 2021-04-22 2024-02-28 Protego Biopharma, Inc. Spirocyclische imidazolidinone und imidazolidindione zur behandlung von leichtkettiger amyloidose
WO2022251533A1 (en) 2021-05-27 2022-12-01 Protego Biopharma, Inc. Heteroaryl diamide ire1/xbp1s activators
WO2022251644A1 (en) 2021-05-28 2022-12-01 Lyell Immunopharma, Inc. Nr4a3-deficient immune cells and uses thereof
US20230052243A1 (en) 2021-06-02 2023-02-16 Lyell Immunopharma, Inc. Nr4a-deficient cells expressing c-jun and uses thereof
CN118696057A (zh) 2021-06-14 2024-09-24 阿根思有限公司 抗il-9抗体及其使用方法
CA3222240A1 (en) 2021-06-16 2022-12-22 Biotheryx, Inc. Sos1 protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
WO2022266249A1 (en) 2021-06-16 2022-12-22 Biotheryx, Inc. Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
EP4410311A4 (de) 2021-09-29 2025-12-17 Nbios Inc Fusionsprotein mit gewickeltem spulenkern
JP2024539134A (ja) 2021-10-22 2024-10-28 プロセッタ バイオサイエンシズ， インク． 新規な宿主標的汎呼吸器抗ウイルス小分子治療薬
JP2024540411A (ja) 2021-11-08 2024-10-31 プロジェントス・セラピューティクス・インコーポレイテッド 血小板由来成長因子受容体（ｐｄｇｆｒ）アルファ阻害剤及びその使用
US20250099542A1 (en) 2021-12-30 2025-03-27 Neoimmunetech, Inc. Method of treating a tumor with a combination of il-7 protein and vegf antagonist
WO2023129576A2 (en) 2022-01-03 2023-07-06 Lilac Therapeutics, Inc. Acyclic thiol prodrugs
US11932665B2 (en) 2022-01-03 2024-03-19 Lilac Therapeutics, Inc. Cyclic thiol prodrugs
EP4480498A1 (de) 2022-02-17 2024-12-25 NOVELTY NOBILITY Inc. Antikörper-wirkstoff-konjugat
CN118922189A (zh) 2022-03-02 2024-11-08 线粒体能量有限公司 衍生自烟酸和核糖的新型前药
TW202342070A (zh) 2022-03-30 2023-11-01 美商拜奧馬林製藥公司 肌萎縮蛋白外顯子跳躍寡核苷酸
GB2619907A (en) 2022-04-01 2023-12-27 Kanna Health Ltd Novel crystalline salt forms of mesembrine
AU2023252917A1 (en) 2022-04-14 2024-11-28 Bristol-Myers Squibb Company Novel gspt1 compounds and methods of use of the novel compounds
CA3257018A1 (en) 2022-05-05 2023-11-09 Biomarin Pharmaceutical Inc. METHOD FOR TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
AU2023268542A1 (en) 2022-05-10 2024-11-14 Biotheryx, Inc. Cdk protein degraders, pharmaceutical compositions, and therapeutic applications
CA3253951A1 (en) 2022-05-19 2023-11-23 Lyell Immunopharma, Inc. NR4A3 Targeted Polynucleotides and Their Uses
US12180307B2 (en) 2022-06-13 2024-12-31 B.A.I. Laboratories, Llc Interleukin-13 binding cyclic oligopeptides and methods of use thereof
AU2023338217A1 (en) 2022-09-09 2025-04-03 Innovo Therapeutics, Inc. CK1α AND DUAL CK1α / GSPT1 DEGRADING COMPOUNDS
US12171745B2 (en) 2022-09-30 2024-12-24 Boulder Bioscience Llc Compositions and methods for treating non-hemorrhagic closed head injury
AU2023364731A1 (en) 2022-10-21 2025-04-03 Diagonal Therapeutics Inc. Heteromeric agonistic antibodies to il-18 receptor
EP4608838A1 (de) 2022-10-26 2025-09-03 Protego Biopharma, Inc. Spirocyclus mit pyridonverbindungen
EP4608839A1 (de) 2022-10-26 2025-09-03 Protego Biopharma, Inc. Spirocyclen mit bicyclischen heteroarylverbindungen
US20240174673A1 (en) 2022-10-26 2024-05-30 Protego Biopharma, Inc. Spirocycle Containing Pyridine Compounds
WO2024102722A1 (en) 2022-11-07 2024-05-16 Neoimmunetech, Inc. Methods of treating a tumor with an unmethylated mgmt promoter
EP4626864A1 (de) 2022-11-30 2025-10-08 Protego Biopharma, Inc. Lineare heteroaryldiamid-ire1/xbp1s-aktivatoren
EP4626865A1 (de) 2022-11-30 2025-10-08 Protego Biopharma, Inc. Cyclische pyrazoldiamid-ire1/xbp1s-aktivatoren
WO2024194686A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
WO2024194685A2 (en) 2023-03-17 2024-09-26 Oxitope Pharma B.V. Anti-phosphocholine antibodies and methods of use thereof
KR20250168499A (ko) 2023-04-07 2025-12-02 다이애고널 테라퓨틱스 인코포레이티드 액티빈 a 수용체 유사 유형 1(alk1)에 대한 이중 특이적 효현성 항체
US20240383990A1 (en) 2023-04-07 2024-11-21 Diagonal Therapeutics Inc. Hinge-modified bispecific antibodies
WO2024226471A2 (en) 2023-04-24 2024-10-31 Biomarin Pharmaceutical Inc. Compositions and methods for treating stxbp1 disorders
TW202448485A (zh) 2023-05-05 2024-12-16 美商拜奧馬林製藥公司 肌萎縮蛋白外顯子跳躍寡核苷酸
WO2024233642A1 (en) 2023-05-09 2024-11-14 Progentos Therapeutics, Inc. Heterocyclic compounds and uses thereof
US12188328B2 (en) 2023-05-15 2025-01-07 Saudi Arabian Oil Company Wellbore back pressure valve with pressure gauge
US20250019450A1 (en) 2023-05-19 2025-01-16 Diagonal Therapeutics Inc. Bispecific agonistic antibodies to il12 receptor
WO2025010272A1 (en) 2023-07-03 2025-01-09 Neoimmunetech, Inc. Heterodimeric fc molecules and uses thereof
US20250101101A1 (en) 2023-09-01 2025-03-27 iTeos Belgium SA Anti-trem2 antibodies and methods of use
WO2025063888A1 (en) 2023-09-19 2025-03-27 Kancure Pte. Ltd. Survivin-targeted compounds
US20250122182A1 (en) 2023-09-27 2025-04-17 Isosterix, Inc. MYST Inhibitors
WO2025085416A1 (en) 2023-10-16 2025-04-24 Bristol-Myers Squibb Company Gspt1 compounds and methods of use of the compounds
WO2025090519A1 (en) 2023-10-23 2025-05-01 Diagonal Therapeutics Inc. Heteromeric agonistic antibodies to il-18 receptor
GB2636969A (en) 2023-11-24 2025-07-09 Ontrack Therapeutics Ltd Novel crystalline salt forms
WO2025133707A1 (en) 2023-12-19 2025-06-26 Vectory Therapeutics B.V. Anti-tdp-43 antibodies and uses thereof
WO2025147691A1 (en) 2024-01-04 2025-07-10 Innovo Therapeutics, Inc. Compositions and methods for degrading aryl hydrocarbon receptor nuclear translocator protein
WO2025179161A1 (en) 2024-02-21 2025-08-28 Innovo Therapeutics, Inc. Protein degrading compounds
WO2025201633A1 (en) 2024-03-26 2025-10-02 Chen Gefei An agent for reducing amyloid formation
WO2025255341A1 (en) 2024-06-05 2025-12-11 Protego Biopharma, Inc. Tetrahydrofuranyl ire1/xbp1s activators

Family Cites Families (206)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3015128A (en) * 1960-08-18 1962-01-02 Southwest Res Inst Encapsulating apparatus
NL302030A (de) 1962-12-21 1900-01-01
BE661981A (de) * 1964-04-03
US3594326A (en) * 1964-12-03 1971-07-20 Ncr Co Method of making microscopic capsules
US3968203A (en) * 1965-10-01 1976-07-06 Jerome G. Spitzer Aerosol astringent composition
US3401475A (en) * 1966-07-18 1968-09-17 Dow Chemical Co Label and labelled container
US3488714A (en) * 1966-09-19 1970-01-06 Dow Chemical Co Formed laminate structure and method of preparation
US3615972A (en) * 1967-04-28 1971-10-26 Dow Chemical Co Expansible thermoplastic polymer particles containing volatile fluid foaming agent and method of foaming the same
US3532500A (en) * 1967-07-25 1970-10-06 Eastman Kodak Co Light sensitive vesicular composition comprising an azido-s-triazine compound
US3479811A (en) * 1967-11-29 1969-11-25 Dow Chemical Co Yarn and method of making the same
US3732172A (en) * 1968-02-28 1973-05-08 Ncr Co Process for making minute capsules and prefabricated system useful therein
US3649620A (en) * 1969-02-19 1972-03-14 Warner Lambert Co Aldosterone 21-esters and 1-dehydro analogues
US3650831A (en) * 1969-03-10 1972-03-21 Armour Dial Inc Method of cleaning surfaces
US3647784A (en) * 1970-02-02 1972-03-07 American Home Prod Preparation of steroidal formate esters
US4027007A (en) * 1970-12-09 1977-05-31 Colgate-Palmolive Company Antiperspirants formulated with borax
US3873564A (en) * 1971-03-03 1975-03-25 Synvar Ass 2-Imidazolinyl-3-oxide-1-oxypropionic acid
US4108806A (en) * 1971-12-06 1978-08-22 The Dow Chemical Company Thermoplastic expandable microsphere process and product
US4179546A (en) * 1972-08-28 1979-12-18 The Dow Chemical Company Method for expanding microspheres and expandable composition
US3960583A (en) * 1974-05-02 1976-06-01 Philadelphia Quartz Company Method of preparing modified hollow, largely spherical particles by spray drying
CH588887A5 (de) * 1974-07-19 1977-06-15 Battelle Memorial Institute
US3945956A (en) * 1975-06-23 1976-03-23 The Dow Chemical Company Polymerization of styrene acrylonitrile expandable microspheres
US4138383A (en) * 1975-11-24 1979-02-06 California Institute Of Technology Preparation of small bio-compatible microspheres
US4162282A (en) * 1976-04-22 1979-07-24 Coulter Electronics, Inc. Method for producing uniform particles
US4078052A (en) * 1976-06-30 1978-03-07 The United States Of America As Represented By The Secretary Of Health, Education And Welfare Large unilamellar vesicles (LUV) and method of preparing same
GB1599881A (en) * 1977-02-02 1981-10-07 Millington A R Preparation for diagnostic radiology
CH621479A5 (de) * 1977-08-05 1981-02-13 Battelle Memorial Institute
CH624011A5 (de) * 1977-08-05 1981-07-15 Battelle Memorial Institute
US4192859A (en) * 1978-09-29 1980-03-11 E. R. Squibb & Sons, Inc. Contrast media containing liposomes as carriers
US4310506A (en) * 1979-02-22 1982-01-12 California Institute Of Technology Means of preparation and applications of liposomes containing high concentrations of entrapped ionic species
US4276885A (en) * 1979-05-04 1981-07-07 Rasor Associates, Inc Ultrasonic image enhancement
US4265251A (en) * 1979-06-28 1981-05-05 Rasor Associates, Inc. Method of determining pressure within liquid containing vessel
US4310505A (en) * 1979-11-08 1982-01-12 California Institute Of Technology Lipid vesicles bearing carbohydrate surfaces as lymphatic directed vehicles for therapeutic and diagnostic substances
US4342826A (en) * 1980-02-04 1982-08-03 Collaborative Research, Inc. Immunoassay products and methods
US4421562A (en) * 1980-04-13 1983-12-20 Pq Corporation Manufacturing process for hollow microspheres
US4344929A (en) * 1980-04-25 1982-08-17 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4315514A (en) * 1980-05-08 1982-02-16 William Drewes Method and apparatus for selective cell destruction
US4331654A (en) * 1980-06-13 1982-05-25 Eli Lilly And Company Magnetically-localizable, biodegradable lipid microspheres
US4442843A (en) * 1980-11-17 1984-04-17 Schering, Ag Microbubble precursors and methods for their production and use
US4657756A (en) * 1980-11-17 1987-04-14 Schering Aktiengesellschaft Microbubble precursors and apparatus for their production and use
US4681119A (en) * 1980-11-17 1987-07-21 Schering Aktiengesellschaft Method of production and use of microbubble precursors
US4420442A (en) * 1981-04-13 1983-12-13 Pq Corporation Manufacturing process for hollow microspheres
US4533254A (en) * 1981-04-17 1985-08-06 Biotechnology Development Corporation Apparatus for forming emulsions
EP0068961A3 (de) * 1981-06-26 1983-02-02 Thomson-Csf Vorrichtung zur lokalen Erwärmung von biologischen Gewebe
US4534899A (en) * 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4426330A (en) * 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4569836A (en) * 1981-08-27 1986-02-11 Gordon Robert T Cancer treatment by intracellular hyperthermia
WO1983001068A1 (en) * 1981-09-23 1983-03-31 Baker, Alfred, George Hollow, bilayered silicate microspheres
DE3141641A1 (de) * 1981-10-16 1983-04-28 Schering Ag, 1000 Berlin Und 4619 Bergkamen Ultraschall-kontrastmittel und dessen herstellung
US4540629A (en) * 1982-04-08 1985-09-10 Pq Corporation Hollow microspheres with organosilicon-silicate walls
FR2534487B1 (fr) 1982-10-15 1988-06-10 Dior Christian Parfums Procede d'homogeneisation de dispersions de phases lamellaires lipidiques hydratees, et suspensions obtenues par ce procede
EP0111386B1 (de) * 1982-10-26 1987-11-19 University Of Aberdeen Ultraschallanlage zur Hyperthermie
US4603044A (en) * 1983-01-06 1986-07-29 Technology Unlimited, Inc. Hepatocyte Directed Vesicle delivery system
US4731239A (en) * 1983-01-10 1988-03-15 Gordon Robert T Method for enhancing NMR imaging; and diagnostic use
US4572203A (en) * 1983-01-27 1986-02-25 Feinstein Steven B Contact agents for ultrasonic imaging
US4718433A (en) 1983-01-27 1988-01-12 Feinstein Steven B Contrast agents for ultrasonic imaging
US4775522A (en) * 1983-03-04 1988-10-04 Children's Hospital Research Foundation, A Division Of Children's Hospital Medical Center NMR compositions for indirectly detecting a dissolved gas in an animal
US4981692A (en) * 1983-03-24 1991-01-01 The Liposome Company, Inc. Therapeutic treatment by intramammary infusion
US5141738A (en) 1983-04-15 1992-08-25 Schering Aktiengesellschaft Ultrasonic contrast medium comprising gas bubbles and solid lipophilic surfactant-containing microparticles and use thereof
US4544545A (en) * 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US4900540A (en) * 1983-06-20 1990-02-13 Trustees Of The University Of Massachusetts Lipisomes containing gas for ultrasound detection
US4615879A (en) * 1983-11-14 1986-10-07 Vanderbilt University Particulate NMR contrast agents for gastrointestinal application
FR2563725B1 (fr) * 1984-05-03 1988-07-15 Dory Jacques Appareil d'examen et de localisation de tumeurs par ultrasons muni d'un dispositif de traitement localise par hyperthermie
JPH0753661B2 (ja) * 1984-03-08 1995-06-07 フアレス フアーマスーチカル リサーチ エヌブイ プロ―リポソーム組成物及びリポソームの水性分散物を作る方法
GB8407557D0 (en) * 1984-03-23 1984-05-02 Hayward J A Polymeric lipsomes
US4728575A (en) * 1984-04-27 1988-03-01 Vestar, Inc. Contrast agents for NMR imaging
US5008050A (en) * 1984-06-20 1991-04-16 The Liposome Company, Inc. Extrusion technique for producing unilamellar vesicles
US4620546A (en) * 1984-06-30 1986-11-04 Kabushiki Kaisha Toshiba Ultrasound hyperthermia apparatus
US4789501A (en) * 1984-11-19 1988-12-06 The Curators Of The University Of Missouri Glass microspheres
US4921706A (en) * 1984-11-20 1990-05-01 Massachusetts Institute Of Technology Unilamellar lipid vesicles and method for their formation
US4830858A (en) * 1985-02-11 1989-05-16 E. R. Squibb & Sons, Inc. Spray-drying method for preparing liposomes and products produced thereby
US4689986A (en) * 1985-03-13 1987-09-01 The University Of Michigan Variable frequency gas-bubble-manipulating apparatus and method
US5186922A (en) 1985-03-15 1993-02-16 See/Shell Biotechnology, Inc. Use of biodegradable microspheres labeled with imaging energy constrast materials
US4871488A (en) * 1985-04-22 1989-10-03 Albany Medical College Of Union University Reconstituting viral glycoproteins into large phospholipid vesicles
US4663161A (en) * 1985-04-22 1987-05-05 Mannino Raphael J Liposome methods and compositions
DE3664869D1 (en) * 1985-05-15 1989-09-14 Ba Inpharm Bv Pharmaceutical compositions of the prodrug type, a process for the preparation thereof, a process for the preparation of them as prodrug functioning compounds and compounds obtained therein
AU587472B2 (en) * 1985-05-22 1989-08-17 Liposome Technology, Inc. Liposome inhalation method and system
JPH0750556B2 (ja) * 1985-06-26 1995-05-31 日本電気株式会社 半導体記憶装置
EP0216730B1 (de) 1985-08-12 1991-01-23 Battelle Memorial Institute Poröse Filtrierungsglaskugeln und Methode zu deren Herstellung
US4684479A (en) * 1985-08-14 1987-08-04 Arrigo Joseph S D Surfactant mixtures, stable gas-in-liquid emulsions, and methods for the production of such emulsions from said mixtures
US4938947A (en) * 1985-11-01 1990-07-03 Centre National De La Recherche Scientifique (Cnrs) Aerosol composition for in vivo imaging
US4927623A (en) * 1986-01-14 1990-05-22 Alliance Pharmaceutical Corp. Dissolution of gas in a fluorocarbon liquid
US4865836A (en) * 1986-01-14 1989-09-12 Fluoromed Pharmaceutical, Inc. Brominated perfluorocarbon emulsions for internal animal use for contrast enhancement and oxygen transport
US4987154A (en) * 1986-01-14 1991-01-22 Alliance Pharmaceutical Corp. Biocompatible, stable and concentrated fluorocarbon emulsions for contrast enhancement and oxygen transport in internal animal use
DE3785054T2 (de) 1986-01-24 1993-07-08 Childrens Hosp Medical Center Stabile emulsionen von stark fluorierten, organischen verbindungen.
US4737323A (en) * 1986-02-13 1988-04-12 Liposome Technology, Inc. Liposome extrusion method
JPH0751496B2 (ja) * 1986-04-02 1995-06-05 武田薬品工業株式会社 リポソ−ムの製造法
DE3614657A1 (de) 1986-04-30 1987-11-05 Dornier Medizintechnik Pharmaka enthaltende lipidvesikel, verfahren zu ihrer herstellung und einbringung in den koerper eines lebewesens und freisetzung der in den lipidvesikeln enthaltende pharmaka
US5268456A (en) 1986-05-15 1993-12-07 E. I. Du Pont De Nemours And Company Bioaffinity and ion exchange separations with liquid exchange supports
FR2602774B1 (fr) * 1986-07-29 1990-10-19 Atta Nouvelles molecules amphiphiles polyhydroxylees et perfluoroalkylees ayant des proprietes tensioactives
IL79559A0 (en) 1986-07-29 1986-10-31 Univ Ramot Contrast agents for nmr medical imaging
US4728578A (en) * 1986-08-13 1988-03-01 The Lubrizol Corporation Compositions containing basic metal salts and/or non-Newtonian colloidal disperse systems and vinyl aromatic containing polymers
US4776991A (en) * 1986-08-29 1988-10-11 The United States Of America As Represented By The Secretary Of The Navy Scaled-up production of liposome-encapsulated hemoglobin
US4781871A (en) * 1986-09-18 1988-11-01 Liposome Technology, Inc. High-concentration liposome processing method
ZW11287A1 (en) * 1986-11-04 1989-01-25 Aeci Ltd Process for the production of an explosive
DE3637926C1 (de) 1986-11-05 1987-11-26 Schering Ag Ultraschall-Manometrieverfahren in einer Fluessigkeit mittels Mikroblaeschen
US5049388A (en) * 1986-11-06 1991-09-17 Research Development Foundation Small particle aerosol liposome and liposome-drug combinations for medical use
US4863717A (en) * 1986-11-10 1989-09-05 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of The University Of Oregon Methods for circumventing the problem of free radial reduction associated with the use of stable nitroxide free radicals as contrast agents for magnetic reasonance imaging
US4933121A (en) * 1986-12-10 1990-06-12 Ciba Corning Diagnostics Corp. Process for forming liposomes
DK175531B1 (da) 1986-12-15 2004-11-22 Nexstar Pharmaceuticals Inc Leveringsvehikel med amphiphil-associeret aktiv bestanddel
CA1321048C (en) * 1987-03-05 1993-08-10 Robert W. J. Lencki Microspheres and method of producing same
US5000960A (en) * 1987-03-13 1991-03-19 Micro-Pak, Inc. Protein coupling to lipid vesicles
US5219538A (en) 1987-03-13 1993-06-15 Micro-Pak, Inc. Gas and oxygen carrying lipid vesicles
CH672733A5 (de) 1987-05-22 1989-12-29 Bracco Ind Chimica Spa
US5354549A (en) 1987-07-24 1994-10-11 Nycomed Imaging As Iodinated esters
DE3741201A1 (de) 1987-12-02 1989-06-15 Schering Ag Ultraschallarbeitsverfahren und mittel zu dessen durchfuehrung
IE61591B1 (en) 1987-12-29 1994-11-16 Molecular Biosystems Inc Concentrated stabilized microbubble-type ultrasonic imaging agent and method of production
US4844882A (en) * 1987-12-29 1989-07-04 Molecular Biosystems, Inc. Concentrated stabilized microbubble-type ultrasonic imaging agent
US5425366A (en) 1988-02-05 1995-06-20 Schering Aktiengesellschaft Ultrasonic contrast agents for color Doppler imaging
US4898734A (en) * 1988-02-29 1990-02-06 Massachusetts Institute Of Technology Polymer composite for controlled release or membrane formation
DE3812816A1 (de) 1988-04-16 1989-11-02 Lawaczeck Ruediger Dipl Phys P Verfahren zur solubilisierung von liposomen und/oder biologischer membranen sowie deren verwendung
US5171755A (en) 1988-04-29 1992-12-15 Hemagen/Pfc Emulsions of highly fluorinated organic compounds
US4893624A (en) * 1988-06-21 1990-01-16 Massachusetts Institute Of Technology Diffuse focus ultrasound hyperthermia system
US4993415A (en) * 1988-08-19 1991-02-19 Alliance Pharmaceutical Corp. Magnetic resonance imaging with perfluorocarbon hydrides
US4996041A (en) * 1988-08-19 1991-02-26 Toshiyuki Arai Method for introducing oxygen-17 into tissue for imaging in a magnetic resonance imaging system
DE3828905A1 (de) 1988-08-23 1990-03-15 Schering Ag Mittel bestehend aus cavitate oder clathrate bildenden wirt/gast-komplexen als kontrastmittel
US5045304A (en) * 1988-08-31 1991-09-03 Wayne State University Contras agent having an imaging agent coupled to viable granulocytes for use in magnetic resonance imaging of abscess and a method of preparing and using same
US5410516A (en) 1988-09-01 1995-04-25 Schering Aktiengesellschaft Ultrasonic processes and circuits for performing them
DE3829999A1 (de) 1988-09-01 1990-03-15 Schering Ag Ultraschallverfahren und schaltungen zu deren durchfuehrung
US4957656A (en) * 1988-09-14 1990-09-18 Molecular Biosystems, Inc. Continuous sonication method for preparing protein encapsulated microbubbles
IL91664A (en) 1988-09-28 1993-05-13 Yissum Res Dev Co Ammonium transmembrane gradient system for efficient loading of liposomes with amphipathic drugs and their controlled release
FR2637182B1 (fr) 1988-10-03 1992-11-06 Lvmh Rech Compositions a base de phases lamellaires lipidiques hydratees ou de liposomes contenant un ecdysteroide, de preference l'ecdysterone, ou l'un de ses derives; et compositions cosmetiques, pharmaceutiques, notamment dermatologiques, de sericulture ou phytosanitaires l'incorporant
US5169836A (en) 1988-11-10 1992-12-08 Trustees Of The University Of Penna. Inhibitors of platelet binding
EP0382451A3 (de) 1989-02-07 1991-05-29 Merck & Co. Inc. Polypeptide und deren Varianten aus dem Gift von Schlangen
US5114703A (en) 1989-05-30 1992-05-19 Alliance Pharmaceutical Corp. Percutaneous lymphography using particulate fluorocarbon emulsions
DK0478686T3 (da) 1989-06-22 1993-11-29 Alliance Pharma Flour- og phosphorholdige amphiphile molekyler med overfladeaktive egenskaber
US5019370A (en) * 1989-07-10 1991-05-28 University Of Kentucky Research Foundation Biodegradable, low biological toxicity radiographic contrast medium and method of x-ray imaging
US5234680A (en) 1989-07-31 1993-08-10 Johns Hopkins Univ. Perfluoro-t-butyl-containing compounds for use in fluorine-19 NMR and/or MRI
US5194266A (en) 1989-08-08 1993-03-16 Liposome Technology, Inc. Amphotericin B/cholesterol sulfate composition and method
NZ235563A (en) 1989-10-13 1993-04-28 Merck & Co Inc Fibrinogen receptor antagonist and pharmaceutical composition
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5620689A (en) 1989-10-20 1997-04-15 Sequus Pharmaceuuticals, Inc. Liposomes for treatment of B-cell and T-cell disorders
US5305757A (en) 1989-12-22 1994-04-26 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5123414A (en) 1989-12-22 1992-06-23 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5149319A (en) 1990-09-11 1992-09-22 Unger Evan C Methods for providing localized therapeutic heat to biological tissues and fluids
US5228446A (en) 1989-12-22 1993-07-20 Unger Evan C Gas filled liposomes and their use as ultrasonic contrast agents
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
US5230882A (en) 1989-12-22 1993-07-27 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5469854A (en) 1989-12-22 1995-11-28 Imarx Pharmaceutical Corp. Methods of preparing gas-filled liposomes
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
US5088499A (en) 1989-12-22 1992-02-18 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
US5542935A (en) 1989-12-22 1996-08-06 Imarx Pharmaceutical Corp. Therapeutic delivery systems related applications
US5352435A (en) 1989-12-22 1994-10-04 Unger Evan C Ionophore containing liposomes for ultrasound imaging
US5209720A (en) 1989-12-22 1993-05-11 Unger Evan C Methods for providing localized therapeutic heat to biological tissues and fluids using gas filled liposomes
US5334381A (en) 1989-12-22 1994-08-02 Unger Evan C Liposomes as contrast agents for ultrasonic imaging and methods for preparing the same
DE4004430A1 (de) 1990-02-09 1991-08-14 Schering Ag Aus polyaldehyden aufgebaute kontrastmittel
US5578292A (en) 1991-11-20 1996-11-26 Bracco International B.V. Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof
US5445813A (en) 1992-11-02 1995-08-29 Bracco International B.V. Stable microbubble suspensions as enhancement agents for ultrasound echography
IN172208B (de) 1990-04-02 1993-05-01 Sint Sa
US5556610A (en) 1992-01-24 1996-09-17 Bracco Research S.A. Gas mixtures useful as ultrasound contrast media, contrast agents containing the media and method
US5358702A (en) 1990-04-10 1994-10-25 Unger Evan C Methoxylated gel particle contrast media for improved diagnostic imaging
US5078994A (en) * 1990-04-12 1992-01-07 Eastman Kodak Company Microgel drug delivery system
US5190982A (en) 1990-04-26 1993-03-02 Hoechst Aktiengesellschaft Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents
US5137928A (en) 1990-04-26 1992-08-11 Hoechst Aktiengesellschaft Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents
US5205287A (en) 1990-04-26 1993-04-27 Hoechst Aktiengesellschaft Ultrasonic contrast agents, processes for their preparation and the use thereof as diagnostic and therapeutic agents
AU636481B2 (en) 1990-05-18 1993-04-29 Bracco International B.V. Polymeric gas or air filled microballoons usable as suspensions in liquid carriers for ultrasonic echography
US5315997A (en) 1990-06-19 1994-05-31 Molecular Biosystems, Inc. Method of magnetic resonance imaging using diamagnetic contrast
US5215680A (en) 1990-07-10 1993-06-01 Cavitation-Control Technology, Inc. Method for the production of medical-grade lipid-coated microbubbles, paramagnetic labeling of such microbubbles and therapeutic uses of microbubbles
DK0504340T3 (da) 1990-10-05 1995-08-21 Bracco Int Bv Fremgangsmåde til fremstilling af stabile suspensioner af hule gasfyldte mikrokugler egnet til ultralyd-ekkografi
US5487390A (en) 1990-10-05 1996-01-30 Massachusetts Institute Of Technology Gas-filled polymeric microbubbles for ultrasound imaging
EP0504881B2 (de) 1991-03-22 2000-11-08 Katsuro Tachibana Verstärker zur Ultraschalltherapie von Erkrankungen sowie diesen enthaltende flüssige Arzneimittelzusammensetzungen
GB9106686D0 (en) 1991-03-28 1991-05-15 Hafslund Nycomed As Improvements in or relating to contrast agents
GB9106673D0 (en) 1991-03-28 1991-05-15 Hafslund Nycomed As Improvements in or relating to contrast agents
US5205290A (en) 1991-04-05 1993-04-27 Unger Evan C Low density microspheres and their use as contrast agents for computed tomography
US5496535A (en) 1991-04-12 1996-03-05 Alliance Pharmaceutical Corp. Fluorocarbon contrast media for use with MRI and radiographic imaging
US5147631A (en) 1991-04-30 1992-09-15 Du Pont Merck Pharmaceutical Company Porous inorganic ultrasound contrast agents
EP0594640A4 (en) 1991-05-23 1998-06-03 Evan C Unger Liposoluble compounds for magnetic resonance imaging
MX9205298A (es) 1991-09-17 1993-05-01 Steven Carl Quay Medios gaseosos de contraste de ultrasonido y metodo para seleccionar gases para usarse como medios de contraste de ultrasonido
RU2114637C1 (ru) 1991-09-17 1998-07-10 Сонус Фармасьютикалз, Инк. Биосовместимая контрастная среда и способ получения ультразвукового изображения
US5409688A (en) 1991-09-17 1995-04-25 Sonus Pharmaceuticals, Inc. Gaseous ultrasound contrast media
US5196183A (en) 1991-12-04 1993-03-23 Sterling Winthrop Inc. Contrast agents for ultrasound imaging
IL104084A (en) 1992-01-24 1996-09-12 Bracco Int Bv Long-lasting aqueous suspensions of pressure-resistant gas-filled microvesicles their preparation and contrast agents consisting of them
WO1993015722A1 (en) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
ATE136457T1 (de) 1992-02-11 1996-04-15 Nexstar Pharmaceuticals Inc Hemmung der aggregaton arzneistoffhaltiger partikeln
JPH06192291A (ja) 1992-09-07 1994-07-12 Nippon Steel Corp 新規ペプチドとそれを用いた血小板凝集抑制剤及び血液凝固抑制剤
US5552155A (en) 1992-12-04 1996-09-03 The Liposome Company, Inc. Fusogenic lipsomes and methods for making and using same
US5558855A (en) 1993-01-25 1996-09-24 Sonus Pharmaceuticals Phase shift colloids as ultrasound contrast agents
DE69427185T2 (de) 1993-01-25 2001-12-06 Sonus Pharmaceutical, Inc. Phase-Stift Kolloide zur Verwendung als Ultraschallkontrastmittel
US5362478A (en) 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
CN1245156C (zh) 1993-02-22 2006-03-15 美国生物科学有限公司 用于体内传送生物制品的方法及用于该方法的组合物
US5567415A (en) 1993-05-12 1996-10-22 The Board Of Regents Of The University Of Nebraska Ultrasound contrast agents and methods for their manufacture and use
US5716597A (en) 1993-06-04 1998-02-10 Molecular Biosystems, Inc. Emulsions as contrast agents and method of use
JP2905598B2 (ja) 1993-07-02 1999-06-14 モレキュラー バイオシステムズ，インコーポレイテッド 熱変性されたタンパク質からカプセル化されたマイクロスフェアを製造する方法
ATE281183T1 (de) 1993-07-30 2004-11-15 Alliance Pharma Stabilisierte mikrogasblaeschen-zusammensetzungen für echografie
US5840707A (en) * 1993-10-04 1998-11-24 Albany Medical College Stabilizing and delivery means of biological molecules
US5994318A (en) * 1993-10-04 1999-11-30 Albany Medical College Cochleate delivery vehicles
US5433204A (en) 1993-11-16 1995-07-18 Camilla Olson Method of assessing placentation
GB9323588D0 (en) * 1993-11-16 1994-01-05 Cortecs Ltd Hydrophobic preparation
US5466467A (en) 1994-03-30 1995-11-14 The United States Of America As Represented By The Secretary Of The Navy Liposomes containing polymerized lipids for non-covalent immobilization of proteins and enzymes
US5502094A (en) 1994-05-20 1996-03-26 Minnesota Mining And Manufacturing Company Physiologically acceptable emulsions containing perfluorocarbon ether hydrides and methods for use
US5562893A (en) 1994-08-02 1996-10-08 Molecular Biosystems, Inc. Gas-filled microspheres with fluorine-containing shells
US5540909A (en) 1994-09-28 1996-07-30 Alliance Pharmaceutical Corp. Harmonic ultrasound imaging with microbubbles
US5512295A (en) 1994-11-10 1996-04-30 The Board Of Trustees Of The Leland Stanford Junior University Synthetic liposomes for enhanced uptake and delivery
EP0727225A3 (de) 1995-02-14 1997-01-15 Sonus Pharma Inc Zusammensetzungen und Verfahren zur Herstellung von gerichteter Ultraschallabbildung
US5830430A (en) * 1995-02-21 1998-11-03 Imarx Pharmaceutical Corp. Cationic lipids and the use thereof
US5560364A (en) 1995-05-12 1996-10-01 The Board Of Regents Of The University Of Nebraska Suspended ultra-sound induced microbubble cavitation imaging
US5558092A (en) 1995-06-06 1996-09-24 Imarx Pharmaceutical Corp. Methods and apparatus for performing diagnostic and therapeutic ultrasound simultaneously
US5997898A (en) * 1995-06-06 1999-12-07 Imarx Pharmaceutical Corp. Stabilized compositions of fluorinated amphiphiles for methods of therapeutic delivery
US5606973A (en) 1995-06-07 1997-03-04 Molecular Biosystems, Inc. Liquid core microdroplets for ultrasound imaging
US5851536A (en) * 1995-11-22 1998-12-22 University Of Washington Therapeutic delivery using compounds self-assembled into high axial ratio microstructures
US5849727A (en) 1996-06-28 1998-12-15 Board Of Regents Of The University Of Nebraska Compositions and methods for altering the biodistribution of biological agents
US5846517A (en) 1996-09-11 1998-12-08 Imarx Pharmaceutical Corp. Methods for diagnostic imaging using a renal contrast agent and a vasodilator
US6090800A (en) 1997-05-06 2000-07-18 Imarx Pharmaceutical Corp. Lipid soluble steroid prodrugs
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
US6143276A (en) 1997-03-21 2000-11-07 Imarx Pharmaceutical Corp. Methods for delivering bioactive agents to regions of elevated temperatures
US6187335B1 (en) * 1997-12-31 2001-02-13 Orasomal Technologies, Inc. Polymerizable fatty acids, phospholipids and polymerized liposomes therefrom
DE69920425T2 (de) * 1998-04-09 2005-09-29 Amersham Health As Verwendung von teilchenförmigen kontrastmitteln in der diagnostischen bilderzeugung zur untersuchung physiologischer parameter

Also Published As

Publication number Publication date
EP1037673A1 (de) 2000-09-27
DE69835692D1 (de) 2006-10-05
AU6185398A (en) 1998-10-20
US6120751A (en) 2000-09-19
EP1037673A4 (de) 2002-05-02
US6403056B1 (en) 2002-06-11
EP1037673B1 (de) 2006-08-23
US6808720B2 (en) 2004-10-26
WO1998042383A1 (en) 1998-10-01
US20030054027A1 (en) 2003-03-20

Similar Documents

Publication Publication Date Title
ATE337019T1 (de) Geladene lipide und deren verwendung
CY1108610T1 (el) Πεπτιδια της il-2 και παραγωγα αυτων και χρηση αυτων ως θεραπευτικοι παραγοντες
CY1119369T1 (el) Ιατρικα παρασκευασματα για τη θεραπευτικη αγωγη της ανεπαρκειας της αλφα-γαλακτοσιδασης α
FI971776A0 (fi) Yhdisteet ja koostumukset aktiivisten aineiden antamiseksi
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
TR199903034T2 (xx) Piperazin t�revleri ve anti-enflamatuvar ajan olarak kullan�mlar�.
ATE206041T1 (de) Polyether-blockcopolymer micellare zusammensetzungen zur zielgerichteten verabreichung biologischer stoffe
PT1093819E (pt) Compostos e composicoes para fornecimento de agentes activos
MX9306239A (es) Composicion farmaceutica que forma un gel de lecitina in vivo para la liberacion mantenida de un compuesto biologicamente activo y procedimiento para la preparacion de la misma.
PT902789E (pt) Derivados de androsteno
NO962088D0 (no) Preparat for in vivo-produksjon av terapeutiske produkter
DE69519802D1 (de) Etherlipid-liposomen und deren therapeutische verwendung
ATE355288T1 (de) Verbindungen und therapeutische methoden
BG106155A (en) Novel derivatives and analogues of galanthamin
IT1270618B (it) Proteine ad attivita' antitumorale
ATE199641T1 (de) Terpenderivate (sarcodictyine) als antikrebsmittel
PT1124577E (pt) Utilizacao de uma proteina ompa de enterobacteria para o direccionamento especifico para as celulas apresentadoras de antigenios
ID23184A (id) Garam-garam peptida bpc dengan aktivitas organoprotektif proses pembuatan dan penggunaannya dalam terapi
EA200401295A1 (ru) Статиновая терапия для усиления поддержания когнитивной функции
GB9921985D0 (en) Medicaments containing pantothenic acid
AR012107A1 (es) Lipidos cargados, composiciones que comprenden lipidos cargados y el uso de estas composiciones en la aplicacion de drogas
ES2181160T3 (es) Derivados de 1,4-dihidropiridina y su utilizacion en terapia.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties